Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  1 of 79  
 Medical  Monitor:  Oliver  Medzihradsky  , 
 MPH  
 Dynavax  Technologies  Corporation  
0
 Tel: + (415)  
 8063  mail
 o
 edzihradsky  @dynavax.com  
Clinical  Operations:  Tammy  Boyce, MEd  
Senior  Director,  Clinical  Operations  
Dynavax  Technologies  Corporation  
3
 Tel: +1  (619) 93 7176   
 
Protocol Title:  Phase 2, Randomized, Active-Controlled, Observer -Blinded, 
Multicenter  Trial of the Immunogenicity,  Safety, and  Tolerability of 
rF1V Vaccine with CpG 1018 Compared with rF1V Vaccine in 
Adults 18 to 55 Years of Age  
Protocol  No.: DV2 -PLG-01 
Investigational  Product:  rF1V Vaccine with CpG 1018  
 
Study  Phase:  2 
US IND Number:  028166 
Sponsor:  Dynavax  Technologies  Corporation 
2100 Powell Street, Suite 720  
Emeryville, CA 94608 
U.S.A  
 
Oliver  , MDMPH  MS  
Tel: +1 (415)  310 8063  E-mail:  edzihradsky@dynavax.com  
Tammy  Boyce, MEd     
  
Tel: +1 (619)  933 7176    
E-mail:  tboyce@dynavax.com   
 
Original Protocol:  07 March  2022 
Amendment  1: 11May 2022 
Amendment  2: 01 June 2022 
Amendment  3: 06 June 2022 
Amendment  4 07 December  2022 
Amendment  5 11 August  2023  
This study will be conducted in accordance with good clinical practice (GCP)  as defined  in International 
Council for Harmonisation (ICH) Guidelines E6 (R2) and applicable local legal and regulatory 
requirements.  Clinical  Operations:  Medical Monitor  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  2 of 79  
 PROTOCOL APPROVAL PAGE 
Protocol Title: Phase 2, Randomized, Active-Controlled, Observer-Blinded, 
Multicenter Trial of the Immunogenicity, Safety, and 
Tolerability  of rF1V  Vaccine with CpG 1018 Compared  with 
rF1V Vaccine in Adults 18 to 55 Years of Age  
Protocol No.: DV2 -PLG -01 
Amendment  5: 11 August 2023  
Sponsor:  Dynavax Technologies Corporation  
2100 Powell  Street,  Suite  720 Emeryville,  CA 94608 
U.S.A.  
 
  
 
This protocol  has been  approved by Dynavax Technologies Corporation. The following 
signature documents this approval.  
 
 
  
 
  
 
  
 
  
 
  
 
  
 
 
 
15-Aug-2023 I 11:25 PDT 
Ouzama  Henry,  MD 
Vice  President,  Clinical  Development  
Date 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  3 of 79  
 INVESTIGATOR SIGNATURE PAGE  
Protocol Title: Phase 2, Randomized, Active -Controlled, Observer -Blinded, 
Multicenter Trial of the Immunogenicity, Safety, and 
Tolerability  of rF1V  Vaccine with CpG 1018 Compared  with 
rF1V Vaccine in Adults 18 to 55 Years of Age  
 
 
Protocol  No.: DV2 -PLG -01 
Amendment  5: 11 August  2023  
Sponsor:  Dynavax Technologies  Corporation 
2100 Powell Street, Suite 720 
Emeryville,  CA 94608 
U.S.A.  
 
 
 
DECLARATION OF INVESTIGATOR  
I confirm that I have read and understood this protocol and agree to conduct the study as 
outlined in the  protocol and other information supplied to me. I agree to conduct the  study in 
accordance with ICH GCP  guidelines, and applicable  local  legal  and regulatory  requirements.  
 
 
 
 
Investigator  Signature  Date 
 
 
 
  
 
Investigator  Name  (Print) 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  4 of 79  
 TABLE  OF CONTENTS  
LIST OF TABLES  ........................................................................................................................ 7 
LIST OF APPENDICES  ............................................................................................................... 7 
PROTOCOL SYNOPSIS ..............................................................................................................8  
1 LIST OF ABBREVIATIONS  AND DEFINITIONS  OF TERMS  .............................. 20 
2 INTRODUCTION AND RATIONALE ........................................................................ 22 
2.1 Plague  (Yersinia  pestis)  ......................................................................................... 22 
2.2 rF1V  Vaccine Background  .................................................................................... 22 
2.3 Clinical Experience  with rF1V Vaccine ................................................................ 23 
2.3.1 Effectiveness  Data  with rF1V  Vaccine – Bridge  Strategy  ................... 23 
2.3.2 rF1V  Mechanism  of Action  .................................................................. 23 
2.3.3 Clinical Evaluation of rF1V  Plague  Vaccine  ........................................24 
2.4 CpG 1018 Background  .......................................................................................... 26 
2.4.1 CpG 1018 Mechanism  of Action  .......................................................... 26 
2.4.2 Review  of Available  Clinical  Data  Supporting Rationale  for CpG 
1018 with rF1V  Antigen ....................................................................... 26 
2.5 Study Rationale  and Doses to Be Evaluated  ......................................................... 30 
3 STUDY OBJECTIVES  AND ENDPOINTS  ................................................................. 31 
4 INVESTIGATIONAL PLAN ......................................................................................... 36 
4.1 Study Design  ......................................................................................................... 36 
4.2 Study Duration  ...................................................................................................... 37 
4.3 Randomization and Blinding  ..................................................................................37 
4.4 Appropriateness  of Measurements  .........................................................................37 
5 SELECTION OF SUBJECTS  ........................................................................................ 38 
5.1 Inclusion Criteria  ................................................................................................... 38 
5.2 Exclusion Criteria  .................................................................................................. 39 
5.3 Criteria for Discontinuation of Individual Subjects From Receiving Additional 
Study Injections  ..................................................................................................... 40 
5.4 Removal of  Subjects  From the  Study .....................................................................40 
5.5 Replacement  of Subjects  ....................................................................................... 41 
5.6 Study Termination  ................................................................................................. 41 
6 STUDY TREATMENT  AND SUPPLIES  ..................................................................... 42 
6.1 Study Treatments  ................................................................................................... 42 
6.1.1 rFIV  Vaccine ........................................................................................ 42 
6.1.2 CpG 1018 ............................................................................................. 42 
6.1.3 Placebo  ..................................................................................................42 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  5 of 79  
 6.2 Instructions for Preparation  and Administration  .................................................... 42 
6.2.1 rFIV  vaccine and CpG  1018 Preparation  .............................................. 42 
6.2.2 Study Vaccine Administration  ............................................................... 42 
6.3 Labeling  .................................................................................................................. 43 
6.4 Storage  and Handling Instructions  ......................................................................... 44 
6.4.1 rF1V  and CpG 1018  .............................................................................. 44 
6.4.2 Bedside  mix of rF1V  vaccine and CpG 1018  ........................................ 44 
7 TREATMENT OF SUBJECTS  ...................................................................................... 44 
7.1 Study Treatments  .................................................................................................... 44 
7.2 Dosage  and Dosage  Regimen  ................................................................................. 45 
7.3 Treatment  Compliance  ........................................................................................... 45 
7.4 Control  and Accountability of Investigational  Medicinal  Product  ......................... 46 
7.5 Concomitant  Medications ....................................................................................... 46 
7.5.1 Prohibited Treatments or Therapies  ...................................................... 46 
7.5.2 Permitted  Therapy  ................................................................................. 47 
8 MANAGEMENT OF SUBJECT SAFETY ................................................................... 48 
8.1 Data Monitoring  Committee  .................................................................................. 48 
8.2 Potential  Reasons  for Stopping the Study  .............................................................. 48 
8.3 Injection  Site Reactions  .......................................................................................... 48 
8.4 Observation  Period  After Study  Vaccine Injection  ................................................ 48 
8.5 Other  Supportive  Care ............................................................................................ 48 
9 STUDY PROCEDURES  .................................................................................................. 50 
9.1 Informed Consent, Screening, and Eligibility  ........................................................ 50 
9.1.1 Informed  Consent  .................................................................................. 50 
9.1.2 Screening  and Eligibility  ....................................................................... 50 
9.1.3 Demographics  and Medical  and Medication  History  ............................ 50 
9.2 Study Visits  ............................................................................................................ 51 
9.3 Immunogenicity Assessments ................................................................................ 51 
9.3.1 Antibodies  to rF1V  ................................................................................ 51 
9.4 Safety  Assessments  ................................................................................................ 51 
9.4.1 Vital Signs  ............................................................................................. 51 
9.4.2 Physical  Examinations  ........................................................................... 52 
9.4.3 Laboratory  Assessments.  ....................................................................... 52 
9.4.4 Post-Injection  Reaction  Assessments  .................................................... 52 
9.4.5 Adverse  Events  ...................................................................................... 53 
9.4.6 Concomitant  Medications ...................................................................... 54 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  6 of 79  
 9.5 Unscheduled Visit for Safety  ................................................................................ 54 
9.6 Duration  of Follow -up ........................................................................................... 54 
9.7 Early  Discontinuation/End of Study  ..................................................................... 54 
10 ADVERSE EVENTS  ....................................................................................................... 55 
10.1 Definition  of Adverse Events  ................................................................................ 55 
10.2 Definition  of Post-Injection Reactions .................................................................. 56 
10.3 Overdoses  .............................................................................................................. 56 
10.4 Adverse  Events  Associated  With  Cancer  .............................................................. 56 
10.5 Definition  of Adverse Reaction  ............................................................................. 56 
10.6 Definition  of Suspected Adverse Reaction  ........................................................... 56 
10.7 Definition of Unexpected Adverse Event or Unexpected Suspected Adverse 
Reactions  ................................................................................................................57 
10.8 Definition  of Immune -mediated Adverse Event  of Special  Interest  ..................... 57 
10.9 Serious  Adverse Events  ......................................................................................... 57 
10.9.1 Definition  of Serious Adverse Events  .................................................. 57 
10.9.2 Serious  Adverse Event  Reporting Requirements  ................................. 58 
10.10 Adverse  Event  Severity  and Relationship  to Study  Treatment  ............................. 59 
10.10.1 Severity Grading of Adverse Events and Abnormal Laboratory Test 
Results  .................................................................................................. 59 
10.10.2 Relationship  of Adverse  Events  to Study Treatment  ............................ 59 
10.11 Reporting and Documentation of Pregnancy and Exposure  during 
Breastfeeding  ..........................................................................................................60 
11 STATISTICAL METHODS  ............................................................................................62 
11.1 Sample Size Considerations  ...................................................................................62 
11.2 Study Analysis  Populations  ................................................................................... 63 
11.3 Demographics  and Baseline Characteristics ...........................................................63 
11.4 Immunogenicity  Endpoints  ................................................................................... 63 
11.5 Safety  Analyses  ..................................................................................................... 64 
11.6 Interim Analysis  .................................................................................................... 65 
12 DATA QUALITY ASSURANCE ................................................................................... 65 
13 ETHICS  ............................................................................................................................ 65 
13.1 Ethical Conduct  of the Study  ................................................................................ 65 
13.2 Informed  Consent  .................................................................................................. 65 
13.3 Subject  Confidentiality  .......................................................................................... 66 
13.4 Data  Handling and Record Keeping  ..................................................................... 66 
13.4.1 Source  Documents  .................................................................................66 
13.4.2 Direct  Access to Source  Data/Documents ............................................ 67 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  7 of 79  
 13.5 Case Report  Forms  ................................................................................................. 67 
13.6 Data  Handling  ........................................................................................................ 67 
13.7 Coding of  Adverse  Events,  Drugs, and Diseases  ................................................... 68 
13.8 Record Retention  .................................................................................................... 68 
14 USE  OF INFORMATION AND PUBLICATION  ........................................................ 69 
15 REFERENCES  ................................................................................................................. 70 
 
 
LIST OF TABLES  
Table  7-1: Study Treatments ....................................................................................... 45 
Table 10- 1: Grading Scale for Adverse Events Not Included in the CBER 
Guidance  on Toxicity Grading for Healthy  Volunteers  in Vaccine  
Clinical Trials  ............................................................................................. 59 
Table  10-2: Definitions  for Relationship of Adverse  Events  to Study Treatment  ........ 60 
Table  11-1: Precision  Estimate  at Various  Level  of Predicted  Protection  Using  
Clopper  Pearson  CI (N=85)  ...................................................................... 63 
 
 
LIST OF APPENDICES  
Appendix 1: Schedule  of Trial Events  ........................................................................... 73 
Appendix 2:  Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventive Vaccine Clinical Trials  ........................................ 75 
Appendix 3: LIST OF AUTOIMMUNE CONDITIONS  AND  TERMS OF 
SPECIAL INTEREST  ............................................................................... 77 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  8 of 79  
 Bridge  ELIS
 Bridge  ELISA  Bridge  ELISA  
Bridge  ELISA  t 
Bridge  ELISA  57 
 Week  8 
1
 Week  30 PROTOCOL SYNOPSIS 
Protocol Title:  Phase 2, Randomized,  Active-Controlled,  Observer - 
Blinded, Multicenter Trial of the Immunogenicity,  
Safety, and Tolerability of rF1V Vaccine with CpG 
1018 Compared  with rF1V  Vaccine in Adults  18 to 55 
Years of Age 
Study  Objectives and  Endpoints:  
 Objectives Endpoints   
 PART  1 
 Primary  
 • To select one of  the two  methods of 
administration  of rF1V  vaccine with 
CpG 1018 for Part 2 by comparing 
humoral immunization response 28  
days after the second dose  of vaccine  • Ratio of geometric mean ELISA 
concentration  (GMC) between  rF1V 
vaccine with CpG 1018 and rF1V vaccine  
 Secondary  
 • To assess the safety and tolerability of 
rF1V  vaccine  with CpG  1018 compared 
with rF1V vaccine  • Rate of reactogenicity:  solicited  local 
and systemic post-injection reactions  
• Rate of adverse events  (AEs),  severe 
AEs,  serious  adverse events (SAEs), 
immune -mediated adverse events of 
special interest (AESI), and deaths 
 PART  2 
 Primary  
 • To assess the utility of a 2 -dose 
schedule of rF1V vaccine with CpG 1018  as measured  by reduction in time 
to onset of predicted rF1V protection  
 
 
 
 
 
 
 
 
 
• To assess the serum   
antibody concentration to rF1V with 
CpG  1018 compared  with rF1V  vaccine 
28 days after the second dose of vaccine  • Predicted  protection  (percentage  of 
subjects reaching the  
threshold that corresponds to 50% 
predicted  vaccine efficacy)  after 2 doses 
of rF1V vaccine with CpG 1018 compared to that of 3 doses of rF1V 
vaccine  
Criterion for evaluation: Similar 
percentage of subjects reaching the 
hreshold that corresponds 
to 50%  predicted vaccine efficacy after 2 
doses of rF1V vaccine with  CpG  1018 at 
Day Week 8) compared to that after  
3 doses of rF1V vaccine at Day 2 11 
(Week 30 ) 
• Ratio of geometric mean ELISA 
concentration (GMC) between rF1V 
vaccine with CpG 1018 and rF1V 
vaccine 28 days after the second  dose 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  9 of 79  
 Bridge  ELISA  
Bridge  ELISA  
Bridge  ELISA  5
 Week  8 
Week  0/baseline:  prior  to the first 
injection  
Week  4: prior to  the second  
injection:  4 weeks  after the first 
injection  for each vaccine  group.  
Week  8 weeks  after the second  
injection  for each vaccine  group  
Week  12 8 
 after the second  
injection  for each vaccine  group  
Week  16 12 
 after the second  
injection  for each vaccine  group  
Week  30 4 weeks  after third 
injection  for Group  3 26 
 aft e
 second  dose of CpG  1018  
vaccin
 for Groups 1  or 2 
Week  38 12 weeks  after the third 
injection  for Group  3 / 34 
 after the second  injection  for Groups  
1 or 
 Week  50 24 weeks  after the third 
injection  for Group  3 / 46 
 after the second  injection  for Group  
1 or 
  
  Criterion for evaluation : 2-times 
increase in Bridge ELISA GMC point 
estimate after the second dose of rF1V  
vaccine with CpG 1018 to that after the 
second  dose of rF1V vaccine  at Day 57  
 (Week  8)  
 Secondary  
 • To assess the safety and tolerability of 
rF1V vaccine  with CpG 1018 compared 
with rF1V vaccine  • Rate of reactogenicity:  solicited  local 
and systemic post-injection reactions  
• Rate of AEs,  severe AEs,  SAEs,  AESIs, 
and deaths  
 • To assess  the serum  Bridge  ELISA   • GMC and seroconversion rate of serum 
rF1V Bridge ELISA titers at the following  selected  time points  after each 
dose of vaccine: 
• Week  0/baseline 
injection  
• Week 4  prior to the second 
injection: 4 weeks after the first 
injection for each vaccine group.  
• Week  8: 4 weeks after the second 
injection for each vaccine group  
• Week  12: 8 weeks after the second 
injection for each vaccine group  
• Week  16: 12 weeks after the second 
injection for each vaccine group  
• Week  30: 4 weeks after third 
i 3 / 26 weeks  
aft 
vaccine f  
• Week  38: 12 weeks after the third 
i 34 weeks 
a 
1 or 2 
• Week  50: 24 weeks after the third 
injection for Group 3 / 46 weeks  
a 
1 or 2 
Seroconversion is defined as the 
presence of detectable antibody in 
subjects who  had no detectable antibody 
levels at Day l, or a 2' 2--fold increase in 
antibody level in subjects who had detectable antibody levels at Day 1  
Criterion for evaluation: GMC and 
seroconversion  rate point  estimates  from  concentration  to rF1V with  CpG  1018  at 
selected  time points  after each dose 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  10 of 79  
 Exploratory  
To assess  long term clinical  benefit  Risk ratio of subjects  with 2' 6 months  
from rF1V  vaccine  with CpG  1018  clinical  benefit  between  rF1V  vaccine  
compared  with rF1V  vaccine  with CpG  1018  and rF1V  vaccine  
Criterion  for evaluation  6 
 clinical  benefi  t is defined  as retaining the 
predicted  protection  antibody  level a
 months  26 weeks  for rF1V  vaccine  with 
CpG  1018  at Week  30 and 24 
 for 
rF1V  vaccine  at Week  50 after the 
complete  series  . Previous  rF1V  vaccine  
data showed  a small percentage  o
 ubjects  who received 3  doses of  rF1V  
vaccine  had months  clinic  al 
 Similar  levels  are expected  for those  who 
received  rF1V  vaccine  with CpG  1018  a
 Day 211 Week  
 To assess  the utility  of a 2 dose Predicted  protection  using  p eak 
 schedule  of rF1V  vaccine  with CpG rF1V  Bridge  ELISA  concentration  after 
1018  
 measured  by reduction  in time 2 doses of  rF1V vaccine  with CpG 1018  
to onset  of predicted rF1V  compare
 t
 that a
 28 days after 3 
 protection  using  peak  serum  Bridge  of rF1V  vaccine  
ELISA  concentration  Criterion  for evaluation  : Similar  
percentage  of subjects  reaching  the 
Bridge  ELISA  t hreshold  that corresponds  
to 50% predicted  vaccine  efficacy  after 2 
doses  of rF1V  vaccine  with CpG  1018  at 
To assess  the peak  serum  bridge  ELISA  peak  
 Days  57, 85, 113 / Weeks  8, 12, 
concentration  from rF1V  with CpG 1
 ) as compared to  that after  3 doses  of 
1018  compared  with rF1V  vaccine  2
 rF1V  vaccine  at Day 1
 Week  
 days after the complete  series  Ratio  of GMCs  and seroconversion r ate 
betwee
 rF1V  Bridge  E LISA  serum  
concentration  at peak in rF1V vaccine  
with CpG  1018  group  and a
 28 days i
 rF1V  vaccine  group  after the complet  
serie
 Criterion  for evaluation  Similar  GMC  
and seroconversion  rate after 2 doses  of 
rF1V  vaccine  with CpG  1018  at peak 
(Days  57, 85, 113 / Weeks  8, 12,  16 ) 
 compared  to that  after 3 doses  of rF1V  
vaccine  at Day 211 Week  
 To assess  the serum  Bridge  ELISA  GMC  and seroconversion  rate of serum  
concentration  to rF1 and rV with CpG rF1, and rV Bridge  ELISA  titers  at the 
To assess the utility of a 2 -dose  s 
1018  as   
t   
protection    EL    
from rF1V vaccine  
compared  with rF1V  vaccine  Exploratory  rF1V vaccine with CpG 1018 to meet  or 
exceed results from rF1V vaccine at 
relevant visits  
 
• • 
clinical benefit  between  rF1V vaccine 
with CpG 1018 and rF1V vaccine 
• Criterion  for evaluation : 2' 6 months 
clinical benefit 
at 6 
months  (26 weeks for rF1V vaccine with 
CpG 1018 at Week 30 and 24 weeks for rF1V vaccine at Week 50) after the complete series Previous rF1V vaccine 
data showed  of 
subjects who received 3 doses of rF1V vaccine had 2' 6 months  clinical  benefit. 
S 
at 
Day 211 (Week  30). 
• • Predicted  protection  using peak  serum 
concentration after 
2 doses of  rF1V vaccine with  CpG 1018 
c to that at  after 3 doses 
of rF1V vaccine 
Criterion for evaluation  Similar 
percentage of subjects reaching the 
hreshold  
 
•  
 
 
1018 c  rF1V vaccine 28 
days after the complete series  peak  (Days 57, 85, 113 / Weeks 8, 12, 
16 
211 (Week  30) 
• Ratio  of GMCs and seroconversion  rates 
between r   LISA  r 
concentration at peak in rF1V vaccine 
with CpG 1018  and 28 days in  
e 
series  
Criterion  for evaluation : Similar  GMC 
and seroconversion rate after 2 doses of rF1V vaccine with CpG 1018 at peak (Days 57, 85, 113 / Weeks 8, 12, 16)  
 
 
• To assess the serum Bridge ELISA 
concentration  to rF1 and rV with CpG  vaccine at Day 211 (Week  30) 
• GMC  and seroconversion  rate of 
rF1, and rV Bridge ELISA  titers at  the concentration  from  rF1V  with CpG 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  11 of 79  
 1018  at selected  time points  after each following  selected time  points  after each 
dose dose of  vaccine:  
Week  0/baseline:  prior  to the first 
injection  
Week 4:  prior  to the second  
injection:  4 weeks  after the first 
injection  for each vaccine  group.  
Week  8: 4 weeks  after the second  
injection  for each vaccine  group  
Week  12: 8 weeks  after th e 
 injection  for each vaccine  group  
Week  16: 12 weeks after  the second  
injection  for each vaccine  group  
Week  30: 4  weeks after  third 
injection for Group  3 / 26 weeks  
after second dose  of CpG  1018  
vaccine  for Groups  1 or 2 
Week  38: 12  weeks after the third 
injection for Group  3 / 34 weeks  
after the second  injection  for Groups  
1 or 
 Week  50: 24 weeks after  the third 
injection for Group  3 / 46 weeks  
after the second  injection  for Group  
1 or 
 Seroconversion  is defined  as the 
presence  of detectable  a ntibody  in 
subjects  who had no detectable  antibody  
-
 levels  at Day l, or a 2' 2 fold increase  in 
antibody  level  in subjects  who had 
detectable  antibody  levels  at Day  1 
Criterion  for evaluation  GMC  and 
seroconversion  rate point  estimates  from  
rF1V  vaccine  wi th CpG  1018  to meet  or 
exceed  results  from  rF1V  vaccine  a
 relevant  visits  
and 29 (and placebo  at Day 183 
, 2
 and 183 
1 and 29 (and placebo  at Day 183)  
dose f each 
dose of  vaccine  
• 
injection  
• Week 4: prior to the second 
injection: 4 weeks after the first 
injection for each vaccine group.  
• Week  8: 4 weeks after the second 
injection for each vaccine group  
• Week  12: 8 weeks after the second 
injection for each vaccine group  
• Week  16: 12 weeks after the second 
injection for each vaccine group  
• Week  30: 4 weeks after  third 
a 
vaccine for Groups  1 or 2 
• Week  38: 12 weeks after the third 
i 
a 
1 or 2 
• Week  50: 24 weeks after the third 
injection for Group 3 / 46 weeks  
a 
1 or 2 
Seroconversion is defined as the presence of detectable antibody in 
subjects who  had no detectable antibody 
l fold increase in 
antibody level  in subjects who had 
detectable antibody  levels at Day 1 
Criterion  for evaluation : GMC  and 
 
   
 
Study  Design:  rF1V vaccine with CpG 1018 to  eet or 
exceed results from rF1V vaccine at 
relevant visits  
This is a phase 2, randomized, active-controlled, observer - 
blinded, multicenter trial of the immunogenicity, safety, and 
tolerability of rF1V vaccine with CpG 1018 compared  with rF1V 
vaccine alone in adults. Approximately two hundred healthy adults 18 to 55 years of age will be enrolled to compare a two - 
dose regimen of rF1V with CpG 1018 administered on study Days  with a three-dose  
regimen  of rF1V vaccine alone  administered  on study Days 1 29, 
. 
The study will be conducted in 2 parts (Part 1 and Part 2). The 
table below outlines study drug administration in both parts.  
and 183 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  12 of 79  
 and 
 ; and 2 injections  of placebo  will be administered  on 
Day 183 
and 29 and 2 separate  injections  of 
placebo  will be administered  on Day 183 
, 2
 and 183 
Day 
5
 29 When investigational product is co-administered as 2 separate 
injections, the injections  should be administered  in close physical 
proximity to each other (within approximately 1 inch).  
Injections  will be administered  by unblinded study  personnel  not 
otherwise involved in the subjects’ safety evaluation.  Recording 
and evaluation of safety information and laboratory data will be performed by observers blinded to the subjects’ treatment assignment.  
Part  1: 
There will be 2 administration methods  of rF1V vaccine with 
CpG 1018:  
• Group 1 (N = approximately 20): rF1V vaccine and CpG 
1018 will be co-administered  as 2 separate injections  on Days 
1 and 29;  
Day 183. 
• Group 2 (N = approximately 20):  bedside mix of rF1V 
vaccine + CpG 1018 (bedside mix is administered as 1 injection)  and placebo  will be administered  as 2 separate 
injections on Days 1 and 29; a  f 
placebo will be administered on Day 183  
In addition, rFIV  vaccine will be administered  alone  without  CpG 
1018:  
• Group 3 (N = approximately 20): rF1V vaccine and placebo  
will be  administered  as 2 separate injections on  Days 1 , 
 
All Groups  will receive 2 injections  at each treatment  visit to 
maintain the blind.  
A Data Monitoring Committee  (DMC) will review safety  for Part 
1 after the first dose:  
• 72 hours after  first dose in the  first 6 subjects  
• 14 days after first  dose in the first 18 subjects  
In addition,  the DMC  may review safety  data as needed  at any 
time during the study (as defined in the DMC charter).  
The administration method of vaccine utilized in Part 2 of the study will be selected by Dynavax in consultation with the Department of Defense (DoD) after Day 57 immunogenicity data become available to determine whether  the GMC 1  month after 2 
doses of rF1V vaccine with CpG 1018 using the selected administration method is at least 2  times  higher  than that 1 month 
after 2 doses of rF1V vaccine in Group 3. Prior to enrolling subjects in Part 2, the Pharmacy Manual will be updated to document  the method of administration of rF1V vaccine and CpG 
1018 selected for Part 2.  
Part  2: 
Part 2 will begin after immunogenicity  assessments from the Day 
57 visit in Part 1 are completed. The rF1V vaccine with CpG 
and 183. 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  13 of 79  
  
 1018  will be administered  using  the method  selected  from  Part 1 
(Group 1 or Group 2).  
• Group 1 (if selected)  (N=70):  rF1V  co-administered  with 
CpG 1018  
• Group 3 (N=70):  rF1V  co-administered  with placebo  
OR 
• Group 2 (if selected)  (N = 70): bedside  mix of rF1V  and CpG 
1018 
• Group 3 (N=70):  rF1V  
Subjects  will be followed  through Day 393 (Week 56) 
Study  Duration  • The total duration of individual subject participation in the 
Screening  Treatment  and Follow -up parts of this study is up 
to approximately 60 weeks.  
Study  Population:  Adults 18 to 55 years of age 
Planned Number  of 
Participants:  Part 1: N = approximately  60 
Part 2: N = approximately  140 
Eligibility  Criteria:  Inclusion Criteria  
A subject must meet the following criteria to be eligible for 
enrollment  (defined  as receiving  study  treatment)  in the study:  
1) Adults  aged 18  to 55 years  
2) Healthy  participants  or participants  with pre-existing  medical 
conditions who are in a stable medical condition.  
Pre-existing stable medical condition means a subject who: has full capacity of daily activity and no major medication 
modification within 3 months prior to Day 1; has not undergone  surgical  or minimally -invasive intervention  or had 
any hospitalization/emergency room visit for the specific 
medical condition.  
3) Able to comply  with the protocol  schedule and procedures  
4) Able and willing  to provide  written  informed consent  
5) If female of child -bearing  potential and heterosexually  active, 
has practiced adequate contraception for 28 days prior to 
vaccination and has negative pregnancy tests just prior to 
vaccination and has agreed to continue adequate 
contraception until 28 days after vaccination. Adequate 
contraception is defined as a contraceptive method with a 
failure rate of < 1% per year when used consistently and 
correctly and, when applicable, in accordance with the 
product label. Examples include the following:  
• Combined (estrogen and progestogen containing) 
hormonal  contraception  associated  with inhibition  of 
ovulation: oral, intravaginal, or transdermal  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  14 of 79  
  
 • Progestin -only hormonal  contraception  associated  with 
inhibition of  ovulation: oral, injectable, or  implantable  
• Intrauterine  device (IUD) with or without hormonal 
release  
• Vasectomized partner, provided he is the subject’s sole 
partner  and that he has received  a medical  assessment  of 
the surgical success  
• Credible  self-reported  history  of heterosexual  abstinence 
for at least 28 days prior to vaccine administration  
• Female partner  
Female subjects of nonchildbearing potential may be enrolled 
in the study. Nonchildbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral 
oophorectomy, hysterectomy) or postmenopausal (defined as 
amenorrhea for 2' l2 consecutive months prior to Screening without an alternative medical cause).  
Exclusion  Criteria  
A subject  with any 1 of the following  criteria  is not eligible  for 
enrollment (defined as receiving study injection) in the study:  
1) A history  of plague  disease or have  previously received  any 
plague vaccine.  
2) Active tuberculosis  or other  systemic infectious  process.  
3) History  of human  immunodeficiency virus  (HIV),  hepatitis  B 
(HBV) or hepatitis C (HCV) infection, or positive test for antibody to HIV, HBV, or HCV  
4) History  of autoimmune  disorder  
5) History of  sensitivity  to any component  of study vaccines  
6) Body mass index 2' 30 kg/m2  
7) Has received  the following  prior  to the injection:  
• 
:: 14 days:  
• Any licensed  COVID-19 vaccine or any inactivated 
vaccines (including vaccines containing mRNA or CpG)  
• 
:: 28 days:  
• Any live vaccine  
• Systemic corticosteroids (more than 3 consecutive 
days) or other immunomodulators immune 
suppressive medication,  with the exception of inhaled 
steroids  
• Any other  investigational medicinal  agent  
• :: 90 days:  
• Granulocyte  or granulocyte -macrophage  colony- 
stimulating factor  
• Immunoglobulins  or any blood products  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  15 of 79  
 and 2
 , and 2  injections  of 0.25 mL placebo will  be 
administered  on Day 183  
 • Antisense  oligonucleotides  
• Drugs/investigational  agents with very long half-lives  
(defined  as 2' 60 days)  
• At any time:  DNA  plasmids  or other  genetic therapy 
intended to integrate permanently into host cells  
8) If female is pregnant  (known before  or established  at the time 
of screening), breastfeeding, or planning breastfeeding or a 
pregnancy  
9) Is undergoing chemotherapy or expected to receive 
chemotherapy  during the study period;  has a diagnosis  of 
cancer  within  the last 5 years other  than squamous  cell or 
basal cell carcinoma of the skin  
10) History or current evidence of any condition, therapy, or laboratory abnormality  that might  confound the results of the 
study, interfere with the subject's participation for the full 
duration of the study, or is not in the best interest of the 
subject to participate, in the opinion of the treating 
investigator  
11) Oral temperature >100.0°F  at the time of vaccine 
administration.  
12) History  of acute myocardial  infarction  (AMI)  or documented 
coronary artery disease (CAD)  
Study  Treatments:  Investigational  Medicinal Product:  
• Recombinant  F1V (rF1V) plague  antigens  with aluminum 
hydroxide  
• CpG  1018 
• Placebo  (normal  saline)  
 
Dose and Administration:  
When investigational product is co-administered as 2 separate 
injections, the injections  should be administered  in close physical 
proximity to each other (within approximately 1 inch).  
Part 1 
Group 1: 0.5 mL of rF1V vaccine (160 mcg rF1V + 750 mcg alum)  and 0.25 mL of CpG  1018  (3000 mcg)  will be administered 
intramuscularly in  the deltoid  muscle of the non-dominant arm on 
Days 1 and 29,  
administered  on Day 183. 
Group 2: 0.75 mL of the bedside mix of rF1V  vaccine and CpG 
1018 (0.5 mL and 0.25 mL respectively)  and 0.25 mL of placebo 
will be administered  intramuscularly  in the deltoid  muscle  of the 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  16 of 79  
 and 2
 , and 2 injections  of 0.25 mL 
placebo  will be administered  on Day 183 
, 2
 , and 183 
and 2
 , and 2 injections  of 0.25 mL 
placebo  will be administered  on Day 183 
9
 , 2 and 
183. 
and 29; and 0. 5 mL placebo  
will be administered  on Day 183 
9
 , 2 and 183 
and ; and 0 25 non-dominant  arm on Days  1 and 29, 
. 
Group 3: 0.5 mL of rF1V vaccine and 0.25 mL of placebo  will be 
administered intramuscularly in the deltoid muscle of the non- 
dominant arm on Days 1 29, and 183.  
Part 2 
Scenario  1: Group  1 is selected.  
Group 1: 0.5  mL of rF1V vaccine and 0.25  mL of CpG  1018 will 
be administered  intramuscularly  in the deltoid  muscle of the non- 
dominant arm on Days 1  
 
Group 3 : 0.5 mL of rF1V vaccine and 0.25 mL of placebo  will be 
administered intramuscularly in the same or nearby location of 
the deltoid muscle of the non-dominant arm on Days 
183. 
Scenario  2: Group  2 is selected.  
Group 2: 0.75  mL of the  bedside mix of  rF1V vaccine and CpG 
1018 will be administered  intramuscularly  in the deltoid muscle 
of the non-dominant arm on Days 1  
 
Group 3: 0.5 mL of rF1V vaccine will be administered 
intramuscularly the  deltoid  muscle of the non-dominant  arm on 
Days 1 29 and 183  
1 29 and 
will be  administered on  Day 183.  and 29, 
placebo  will be administered  on Day 183 . 
 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  17 of 79  
 Part  
 Dose  1 (Day  Dose  2 (Day  2 Dose  3 ( Day 183 
Group  1 rF1V  vaccine  an
 CpG  1018  coadministration  
Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.25 mL placebo  
Injection  2 0.25 mL CpG 1018  0.25 mL CpG 1018  0.25 mL placebo  
Total  0.75 mL 0.75 mL 0.5 mL 
Group  2 rF1V  vaccine  + CpG  1018  bedside  mix 
Injection  1 0.75 mL rF1V+  0.75 mL rF1V+  0.25 mL placebo  
CpG 1018  CpG 1018  
Injection  2 0.25 mL placebo  0.25 mL placebo  0.25 mL placebo  
Total  1.0 mL 1.0 mL 0.5 mL 
Group  3 rF1V  vaccine  
Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  
Injection  2 0.25 mL placebo  0.25 mL placebo  0.25 mL placebo  
Total  0.75 mL 0.75 mL 0.75 mL 
0.5 mL of rF1V  vaccine  = 160 mcg rF1V  + 750 mcg alum  
0.25 mL of CpG  1018  = 3000  mcg 
Part  
 Scenario  Dose  1 (Day  Dose  2 (Day  2 Dose  3 ( Day 183 
Group  1 rF1V  vaccine  and CpG  1018  coadministration  Scenario  1 Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.25 mL placebo  
(Group  1 and 3) Injection  2 0.25 mL CpG 1018  0.25 mL CpG 1018  0.25 mL placebo  
Total  0.75 mL 0.75 mL 0.5 mL 
Group  3 rF1V  vaccine  
Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  
Injection  2 0.25 mL placebo  0.25 mL placebo  0.25 mL placebo  
Total  0.75 mL 0.75 mL 0.75 mL 
O
 Scenario  2 Group  2 rF1V  vaccine  + CpG  1018  bedside  mix 
(Group  2 and 3) Injection  0.75 mL rF1V+  0.75 
 rF1V+  0.25 mL placebo  
CpG 1018  CpG 1018  
Group  3 rF1V  vaccine  
Injection  0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  0.5 mL of rF1V  vaccine  = 160 mcg rF1V  + 750 mcg alum  
Part  2 
vaccine  1018  bedside  mix 
Group  3 rF1V  vaccine  Study  Vaccine Administration 
Part 1   
 
 
Dose  3 (Day  183) 
 
 
   
    
    
 
0.75 mL rF1V+  
CpG  1018 0.75 mL rF1V+  
CpG  1018 
 
 
    
 
    
    
0.75 mL 
 
0.25 mL of CpG 1018  = 3000 mcg 
 
Dose  3 (Day  183) 
 
  
 
   
 
 
 
OR 
 
0.75 mL rF1V+  0.75 mL rF1V+  
CpG  1018 CpG  1018 
 
    
 
 
0.25 mL of CpG  1018  = 3000 mcg Group  1 rF1V  vaccine  and CpG  1018  coadministration  
I 0.5 mL rF1V  0.5 mL rF1V  
Injection  2 0.25 mL CpG  1018  0.25 mL CpG  1018  0.25 mL placebo  
Total  0.75 mL 0.75 mL 0.5 mL 
Group  2 rF1V  vaccine  CpG  1018  bedside  mix 
I 
Total  1.0 mL 1.0 mL 0.5 mL 
Group  3 rF1V  vaccine  
Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  
Injection  2 0.25 mL placebo  0.25 mL placebo  0.25 mL placebo  
Injection  0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  
0.5 mL of rF1V  vaccine  = 160 mcg rF1V  + 750 mcg alum  
(Group 2 and 3) 
Scenario  2 0.75 mL 0.75 mL 0.75 mL Total  0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  Injection  1 e 0.5 mL 0.75 mL 0.75 mL Total  0.25 mL placebo  0.25 mL CpG  1018  0.25 mL CpG  1018  Injection  2 0.5 mL rF1V  0.5 mL rF1V  Group  1 rF1V  vaccine  and CpG  1018  coadministration   
Scenario 1  
(Group 1 and 3) Dose  2 (Day  29) Dose  1 (Day  1) Scenario  0.75 mL 0.75 mL Total  Dose  2 (Day  29) Dose  1 (Day  1) 
0.25 mL placebo  Injection  0.25 mL placebo  Injection  1 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  18 of 79  
 ridge  ELIS
  
Safety Assessments All subjects  will be monitored  for safety  through  Day 393. 
Safety assessments include the following:  
• Assessment  of post-injection  local  and systemic reaction  (for 
7 days post each injection)  
• Adverse events assessments (AEs,  SAEs,  AESIs, deaths)  
• Vital  signs  measurements 
• Physical examinations  
Stopping  Rules  Dosing  of all subjects  will be temporarily  stopped  for any of the 
following:  
• Two or more subjects who experience Grade 3 (severe) or 
higher  severity  solicited adverse reactions (considered  by the 
sponsor to be possibly or probably related to treatment) lasting more than 48 hours AND considered by the DMC to be clinically significant 
• Two or more subjects who experience the same or similar grade  3 or higher  unsolicited adverse event  that is assessed  as 
at least possibly related to the treatment  
• Any Suspected Unexpected Serious Adverse Reaction 
(SUSAR)  (considered  by the Sponsor  to be possibly or 
probably related to treatment)  
• Any death  or life-threatening  SAE  regardless of relationship 
to vaccine 
• Any type 1  AMI  
Dosing  may be resumed  following review of available safety  data 
by the DMC as specified in the DMC Charter.  
Immunogenicity  Assessments:  Immunogenicity  assessments  include  Serum  rF1V  Bridge  ELISA  
concentration as outlined in the summary of trial events  
Statistical Methods  All analyses  of demographics,  medical  history,  and safety  will be 
summarized in a descriptive manner. In general, continuous variables will be summarized by number of subjects, mean, standard deviation, median, quartiles, minimum and maximum, 
and categorical variables will be summarized by number and 
percentage of subjects in each study group as appropriate. 
The Safety Population will comprise all subjects who receive at least 1 dose of the study vaccine, excluding  subjects who have  no 
on-study data.  
The modified intent -to-treat (mITT) population for the 
immunogenicity analysis will comprise all eligible subjects who 
received  at least 1 dose of study vaccine and have  a post-injection 
immunogenicity evaluation.  
The Per -protocol (PP) population for the immunogenicity 
analyses will comprise Groups 1 and 2 subjects who receive 2 
doses of study vaccine and Group 3 subjects who received 3 doses of study vaccine,  have  no major  protocol  deviations  (to be 
specified  in the  statistical  analysis  plan),  and have 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  19 of 79  
 Bridge  ELISA  
Bridge  ELISA  
Bridge  ELISA  
Bridge  ELISA  
Bridge  
 
Bridge  ELISA  Bridge  ELISA  Bridge  ELISA  Bridge  ELISA  immunogenicity data obtained within  the study visit windows  at 
Day 211.  
The primary and other immunogenicity endpoints will be 
analyzed  using the mITT  population.  Sensitivity  analyses on 
immunogenicity data will also be presented using the PP 
population.  
Immunogenicity will be measured  by serum  rF1V 
concentration at each visit.  
The administration method of vaccine utilized in Part 2 of the study will be selected after Day 57 immunogenicity data become available to determine  whether  the GMC  1 month after 2 doses of 
rF1V vaccine with CpG 1018 using the selected administration 
method is at least 2 times higher than that 1 month after 2 doses 
of rF1V vaccine in Group 3.  
threshold that corresponds to 50% predicted 
vaccine efficacy after 2 doses of rF1V vaccine with CpG 1018 
will be obtained from a model using  data after 3 
doses of rF1V  vaccine (or after 2 doses  of rF1V  with CpG  1018 
TBD) in this study. The threshold and the model used will be 
described in a separate report.  
Predicted protection rate (percentage of subjects reaching the 
threshold)  and associated  95% two-sided  Clopper - 
Pearson confidence intervals will be computed.  Fisher’s exact 
tests will be used to compare  predicted  protection  rate between 
study groups.  
The criterion  for evaluation  of the primary  endpoint  1 in Part 2 is: 
a similar percentage of subjects reaching the 
threshold that corresponds  to 50% predicted  vaccine efficacy  after 
2 doses of rF1V  vaccine  with CpG  1018 as compared  to that after 
3 doses of  rF1V vaccine.  
The criterion  for evaluation  of the primary  endpoint  2 in Part 2 is: 
2-times increase of  GMC point estimate after the 
second dose of rF1V vaccine with CpG 1018 compared to that 
after rF1V vaccine.  
Criteria for secondary objectives are GMC and seroconversion 
rate point estimates  from  rF1V  vaccine with CpG  1018 to meet or 
exceed results from rF1V vaccine at relevant visits 
Safety data will be analyzed descriptively and will be based on 
the Safety  Population.  Summary  statistics will be used to describe 
the incidence of all post -injection reactions, AEs, AESIs, SAEs, 
and deaths. Tables of adverse events will include incidence, severity, seriousness, and relationship to the investigational 
vaccines.  
Data from  Part 1  subjects and Part 2  subjects will be combined to 
evaluate the Part 2 objectives.  Bridge  ELISA  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  20 of 79  
 1 LIST OF ABBREVIATIONS  AND DEFINITIONS  OF TERMS  
AE adverse  event  
AESI  adverse  event  of special  interest  
alum  Aluminum  hydroxide  
AMI acute myocardial  infarction  
ANCA  anti-neutrophil  cytoplasmic  antibodies  
AR adverse  reaction  
BP blood pressure  
CAD  coronary  artery  disease  
CBER  Center  for Biologics  Evaluation  and Research  
CD4+  T-helper  cells 
CFR Code  of Federal  Regulations  
COR  contracting  officer  
CpG cytidine -phospho- guanosine  
CpG 1018 a 22-base cytidine -phospho -guanosine  phosphorothioate  oligodeoxynucleotide 
CRF case report form  
CRO  Contract  Research  Organization  
CSR clinical  study  report  
DMC  data monitoring  committee  
DNA  deoxyribonucleic  acid 
DoD Department  of Defense 
eCRF  electronic  case report  form 
ELISA  enzyme- linked  immunosorbent  assay  
EOS End of Study  (visit)  
EUA  emergency  use authorization 
FDA  Food  and Drug  Administration  
GCP good  clinical practice  
GMC  geometric  mean  concentration  
GMR  geometric  mean  ratio 
GMT  geometric  mean  titer 
HBsAg  hepatitis  B surface  antigen  
HBV  hepatitis  B virus  
HCV  hepatitis  C virus  
HIV human immunodeficiency  virus  
HPV  human papilloma  virus  
HR heart  rate 
 
IB investigators  brochure  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  21 of 79  
 ICF informed consent  form 
ICH International  Council  for Harmonisation 
IM intramuscular  
IMAE  immune -mediated  adverse events  
IND investigational  new drug 
IRB Institutional  Review  Board  
ITAR  International  Traffic  in Arms  Regulations  
IUD intrauterine  device  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
mITT modified  intent -to-treat (population)  
mIU/mL  milli -international  units  per liter 
NIH National  Institutes  of Health  
ODN  oligodeoxynucleotides  
OVRR  Office  of Vaccines  Research  and Review  
PBMC peripheral  blood mononuclear  cell 
PIR post-injection  reactions  
PP per protocol  
PS ODN  phosphorothioate  oligodeoxynucleotide  
rF1V  recombinant  F1 capsular  protein  fused  to V antigen  
RR respiratory  rate 
SAE serious  adverse event  
SAP statistical  analysis  plan 
SAR suspected  adverse  reaction  
SARS -CoV-2 severe acute  respiratory  syndrome  coronavirus  2 
SPR seroprotection  rate 
TC telephone  call 
 
TEAE treatment -emergent  adverse event  
Th T helper  1 cells 
TLR9  Toll-like receptor  9 
UNS  unscheduled 
USG  United  States  Government  
VAERS  Vaccine  Adverse  Event  Reporting  System  
Y. Pestis  Yersinia  pestis  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  22 of 79  
 2 INTRODUCTION AND RATIONALE 
2.1 Plague  (Yersinia  pestis)  
Plague is a zoonotic infection with Yersinia pestis that is normally transmitted from rodents to 
humans  when humans  are bitten by infected  fleas.  There are 3  manifestations  of the disease, with 
flea bites usually causing the bubonic form in which a painful swelling (bubo) of the draining lymph nodes occurs ( Vadyvaloo, Jarrett et al. 2007, Hinnebusch and Erickson 2008). Left 
untreated, the infection will cause sepsis and death in approximately half of the cases. Bubo formation is  not present in the second form of disease, which leads directly to sepsis, and occurs 
in about a third of the cases. Bubonic and septicemic infections occasionally progress to secondary pneumonic infections. Infection with Y. pestis also rarely occurs through inhalation of 
the organism, and, after 1 to 6 days, the  disease manifests in its pneumonic form, which is  nearly 
always fatal unless  the patient  is treated  with antibiotics  within  20 hours  of symptom  onset  (Daya 
and Nakamura 2005) . Clinical signs include fever with cough and dyspnea, and there may be 
production of bloody, watery sputum. Nausea, vomiting, abdominal pain, and diarrhea may also be present. The pneumonic form spreads from person to person by respiratory droplets formed during coughing ( McGovern 1997, Perry and Fetherston 1997, Inglesby, Dennis et al. 2000, 
Koirala 2006, Prentice and Rahalison 2007).  
Historically, plague  (Y. pestis ) has  resulted  in three  pandemics  over the  last 1,700 years.  It is 
estimated to have caused 200 million deaths worldwide. Y. pestis is currently classified as 
a Category A priority  pathogen by both the National  Institute  of Allergy  and Infectious  Diseases 
(NIAID) and the Centers for Disease Control and Prevention (CDC) (Hart, Saviolakis et al.  
2012).  
2.2 rF1V  Vaccine  Background  
The proposed indication for Y. pestis Plague Recombinant Antigen (rF1V; F1 capsular protein 
fused to V antigen; Escherichia coli ) (rF1V Plague Vaccine) is to provide pre -exposure 
prophylaxis  to military  personnel  18 to 55 years of age against  pneumonic  plague  resulting  from 
aerosol exposure to Y. pestis . 
The rF1V plague vaccine candidate was initially developed at the US Army Medical Research 
Institute  for Infectious  Diseases (USAMRIID)  (Hart,  Saviolakis  et al. 2012) . It was  transferred  to 
the Joint Vaccine Acquisition Program (JVAP) (subsequently to the DynPort Vaccine Company 
[DVC], and most recently to the Office of the Surgeon General) in an early stage of 
development. In 2016, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to recombinant rF1V plague vaccine as a biodefense countermeasure on behalf of the U.S. Department of Defense (DoD). The vaccine is intended to be administered to  
individuals considered to be at high risk for exposure to aerosolized Y. pestis . The target 
indication of this vaccine is protection of adults 18 to 55 years of age from disease caused by inhalational exposure to Y. pestis . 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  23 of 79  
 Bridge  ELISA  
Bridge  ELISA  Bridge  ELISA  The rF1V vaccine candidate for plague comprises the F1 capsular protein and the V virulence 
protein  of Y. pestis Colorado 92 (CO92)  fused  into a single protein, which is produced in E. coli 
and formulated with aluminum hydroxide, Alhydrogel® 2%, (alum).  
2.3 Clinical Experience with  rF1V  Vaccine  
The rF1V  vaccine was evaluated  in one Phase 1 (rF1V -01), Phase 2a (rF1V -02a), and 1 phase 2b 
(rF1V -02b) clinical trial. In these clinical trials, assessments of vaccine safety and 
immunogenicity were the major objectives. The immune response to the vaccine was evaluated 
by measurement of the concentration of antibodies to rF1, rV, and rF1V by the  at 
predetermined intervals during the study and calculation of the seroconversion rate. Blood was 
also collected for passive transfer studies for evaluation of efficacy in animals. The safety population included all volunteers who received at least 1 dose of the rF1V vaccine and for 
whom any safety information was recorded. Reactogenicity, tolerability and safety were 
monitored in all vaccinated volunteers at multiple time points after vaccination using physical examination, clinical laboratory tests, and pre -specified or solicited adverse events (AEs) 
collected via volunteer diaries to enhance reporting of AEs by the Investigators.  
2.3.1 Effectiveness Data with  rF1V  Vaccine  – Bridge  Strategy  
The efficacy of the rF1V vaccine as a prophylactic for pneumonic plague, resulting from 
inhalational exposure, cannot be determined directly in humans and, therefore, was evaluated by the Dynport Vaccine Company (DVC) for the DoD in accordance with the Animal Rule. Use of the Animal Rule requires that the pathophysiology of disease and the mechanism by which the vaccine ameliorates disease is well understood in animals. The animal models that  DVC selected 
to evaluate vaccine efficacy were the Swiss Webster mouse and the cynomolgus macaque (CM). 
Aerosol model development studies have been performed in both animal species and have demonstrated sufficient similarity  to the pathology of disease in humans to serve as useful animal 
models for pneumonic plague. DVC evaluated the rF1V vaccine in these animal models for the 
purpose of licensure using the Animal Rule. The agreed bridging strategy for rF1V vaccine was based on modeling the animal survival status (endpoint of interest) as a function of anti- rF1V 
antibody concentration measured by the rF1V (the correlate of protection).  
2.3.2 rF1V  Mechanism  of Action  
Seeking licensure  for a plague vaccine provides unique challenges in that the precise mechanism 
of protection against exposure to Y. pestis is unknown. Both cell- mediated immunity and 
humoral immunity are relevant in providing protection against plague. The agreed bridging strategy for rF1V vaccine is supported by data that demonstrate anti -rF1V antibody 
concentration correlate with rF1V vaccine efficacy in animal models (establishing the relationship between rF1V vaccine dose, anti -rF1V antibody concentration, and survival in the 
Swiss Webster mouse model and cynomolgus macaque following lethal aerosol challenge with  
Y. pestis CO92).  

Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  24 of 79  
 The Phase  1, rF1V  01, clinical trial  was a single  center,  open label trial designed  to evaluate  
(a) the safety,  tolerability  and immunogenicity  of four ascending  doses  (20 mcg , 
 mcg , 
 mcg 
and 160 mcg ) of rF1V  Plague Vaccine with alum  ( Alhydrogel  ® 2
 given as  an 0.5 mL IM 
- injection  at a dose vaccination  regimen  (Day  and 2
 ) and (b) the safety and  tolerability  of a 
third IM  vaccination  of 160 mcg rF1V  Plague Vaccine given on Day 231  in volunteers  
previously  vaccinated  with doses  of 160 mcg rF1V  Plague Vaccine.  The trial  enrolled  44 
v
 lunteers  in a 1:1:1:1  randomization.  Eight  volunteers  from  the 160 mcg group  also received  a 
third  vaccination.  All volunteers  were  followed  for 180 days after the last vaccination.  
Results  from  the Phase 1  trial indicated  that the rF1V  Plague  Vaccine  for mulation  and schedules  
were  safe and that vaccinations  elicited  much  higher  antibody  levels  and higher  seroconversion  
rates  than vaccinations.  Based  on this trial, the highest  doses  (80 mcg and 160 mcg ) were 
e
 selected  for evaluation  in the Phase  2a tr ial in a thre dose vaccination  regimen  
V
 2.3.3.2  Phase  2a Clinical  Trial,  rF1 02(a)  ([STUDY_ID_REMOVED])  
- The Phase 2a,  rF1V  02(a),  clinical trial was  a 
 site, dose blinded,  randomized  trial designed  
to evaluate the  safety, tolerability  and immunogenicity  of dose s (80 mcg and 160 mcg ) 
 - rF1V  Plague  Vaccine  with alum  Alhydrogel  2%) given  as an 0.5  mL IM injection  at two dose 
9
 , , , vaccination  regimens  (Day  1
 and Day 1
 The trial enrolled  400 volunteers  in 
an approximate  1:1:1:1  randomization.  A total of  352 volunteers  reached  Day 210  in the  study,  
and 321 volunteers  were  followed  for 540 days after the first vaccination.  
Results  from the  Phase  2a trial indicated  that th e rF1V  Plague  Vaccine  formulation  and doses  
tested  (80 mcg and 160 mcg ) were  safe and immunogenic. Overall,  the most  frequent  treatment  
, emergent  adverse  events  ( TEAE
 were  local reactions  and the majority  of TEAEs  were  mild or 
. moderate  There  were  no sig nificant  differences  between  dose and treatment  schedules  in the 
incidence  of local  and system  reactions  and other  AEs during  the study.  There  was no significant  
increase  in the incidence  of TEAEs  upon  re vaccination  during  the study.  There  were  no delayed  
immunological  reactions  during  the 12 month  follow  up. The immune  response,  assessed  as 
, anti rF1, anti r
 and anti rF1V  antibody  GMCs  and seroconversion  rates, was  maximal  after 
administration  of the third  vaccination  and it was similar  among  the selecte  d dose and schedules  
following  Vaccination  3. 
The Phase  1, rF1V -01, clinical trial  was a single - 
 -label  trial designed  to evaluate  
(a) the safety, tolerability and immunogenicity of four ascending doses (20  , 40 , 80 
and 160  ) of rF1V Plague Vaccine with alum (Alhydrogel® 2%) given as an 0.5 mL IM 
injection at a 2 dose vaccination regimen (Day 1 and 29) and the safety  and tolerability  of a 
third IM vaccination of 160  rF1V Plague Vaccine given on Day 231 in volunteers 
previously vaccinated with 2 doses of 160  r 1 Plague Vaccine.  he trial enrolled 44  
lunteers in a 1:1:1:1 randomization. Eight volunteers from the 160- group also received  a 
third vaccination. All volunteers were followed for 180 days after the last vaccination.  
2.3.3.2  Phase 2a  Clinical  Trial,  rF1V  02(a)  ([STUDY_ID_REMOVED])  
- 
t 
rF1V  
, 
with alum  ( 
1 29 183 
- 
2 dose 
 and 160 
) 
 3 dose 
1 57 183). The trial enrolled 400  volunteers  in 
. 
and 321 volunteers  
Results  from the  Phase  2a trial indicated  that th 
t and 160 
 ) 
(TEAEs ) were  local  reactions  
treatment - 
moderate 
i 
i 
i 
anti r 
nificant  differences  between  dose and treatment  schedules  in the 
e- 
2- 
i-rV and anti- 
administration of the third vaccination and it was similar  d dose and schedules 
f . Additionally, DVC demonstrated the direct functional relationship between anti -rF1V antibody 
concentration and survival through the conduct of the Protective Capacity Assay (PCA). The 
PCA uses purified  antibodies collected  from rF1V  immunized  animals or humans to measure the 
functional capacity of anti-rF1V antibodies in a mouse model following aerosol challenge with  
Y. pestis.  
2.3.3 Clinical  Evaluation of rF1V  Plague  Vaccine  
2.3.3.1  Phase  1 Clinical Trial,  Protocol rF1V -01 ([STUDY_ID_REMOVED])  
 
 
Results from the Phase 1  trial indicated that the  rF1V Plague Vaccine formulation and schedules 
were  safe and that 3 vaccinations  elicited  much  higher  antibody  levels  and higher  seroconversion  
rates  than 2 vaccinations.  Based  on this trial, the 2 highest  doses  (80 and 160 ) were  
selected  for evaluation  in the Phase  2a trial in a three  dose vaccination regimen.   
 
 
 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
AND  PROPRIETARY  Page  25 of 79 CONFI  NTIALDE CONFIDENTIAL  AND  PROPRIETARY  Page  25 of 79  
 - Figure  Geometric  Mean  Concentrations  o anti rF1V  i
 Phase  2
 2.3.3.2.1  Clinical  Immunogenicity  Data  from  Phase  2a Cohort 3 (IND  #12031)  
Figur
 - 2 1 shows  the GMCs  of anti rF1V  from  the Phase  2a clinical  trial. The highest  rates  of 
seroconversion  were  observed  after 3  doses  of the vaccin
 (160 mcg)  administered  on Days  , 
 and 1
 (Cohort  3 n 
 9
 Seroconversion  was defined  as the presence  of detectable  antibody  
- (defined  as 2' 1
 U/mL)  in subjects  who had no detectable  antibody  levels  at Day 0, or a 2' 2 fold 
increase  in antibody  level  in subjects  who had detectable  antibody  levels  at Day 0. The 
seroconversion  rate for anti rF1V  was 100%  at 7 and 14  days and 96.2%  at 
 months  after the 
third  vaccination.  The seroconversion  rate for anti rF1V at  Day 270 (3 months  following  last 
vaccination)  was 100.0%,  and at Day 364 wa
 98.7%.  All antibodies  
 rF1, anti rV, and 
anti rF1V)  showed  robust  conversion  rates  after Vaccination  3, and the durability  o
 this 
respons
 through  Day 540 wa
 not affected.  Anti rF1V  GM
 a
 days after Vaccination  range
 from 1558.61  U/mL  t
 2619.78  U/mL  at 
 days after Vaccination  
GM
 ranged  from 1166  U/mL  to 1964  U/mL,  and a
 Day 270 range
 from 530 U/mL  t
 910 U/mL. At  Day 540, the GMCs  ranged  from  87 U/mL  to 184 U/mL,  and the great  majority  of 
volunteers  had anti rF1V  levels  above the  lower  limit  of quantification  (LLOQ)  of 10 U/mL.  
The seroconversion  rates  and anti rF1V  antibody  concentr
 tions withi
 the week  period  after 
the third vaccination  were  statistically  similar  in all cohorts  studied  in the Phase  2a trial as well as 
in the Phase  2
 trial. 
The Phase  2b, rF1V -02b, clinical  trial was a multicenter,  single -blinded,  randomized  comparison  
f 2 formulations of rF1V Plague Vaccine (80 mcg), with  and without alum (Alhydrogel 2%) at 
wo 3-vaccination  schedules (Day  1, 57, 122 and Day 1, 57, 183) in 400 healthy adult  volunteers 
n 4 parallel cohorts: 2 rF1V Plague Vaccine cohorts (N=160 each) and 2 rF1V antigen-only 
ohorts (N=40 each). The adjuvanted cohorts had higher GMCs and seroconversion rates than  
seroconversion  rate for anti-rF1V was  100%  at 7 and 14  days and 96.2% at  12 months  after the 
increase  in antibody  level  in subjects  who had detectable  antibody  levels  at Day 0. The 99). Seroconversion  was defined  as the presence  of detectable  antibody  and 183 (Cohort  3 
third  vaccination.  The seroconversion  rate for anti-rF1V  at Day  270 (3  monthsfollowing  last 
anti-rF1V)  showed  robust  conversion  rates  after Vaccination  3, and the durability  of this 
vaccination) was  100.0%, and  at Day 364 a98.7%. All  3 antibodies  (anti-rF1, anti -rV, and 
 
(defined  as 2' 10 U/mL)  in subjects  who had no detectable  antibody  levels  at Day 0, or a 2' 2 fold 
seroconversion  were  observed  after 3 doses  of the  vaccine  (160 mcg)  administered  on Days  1, 29 
Figure  2 1 shows  the GMCs  of anti-rF1V from  the Phase  2a clinical trial.  The highest  rates  of 
; 
r 
 through  Day 540 anot affected  Anti-rF1V  GMC  at 7 days afterVaccination  3 ranged  
from  1558.61  U/mL  to 2619.78  U/mL  at 28  days after Vaccination  3. 
e 2 1: 
 Geometric  Mean  Concentrations f anti-rF1V  in Phase  2a 
 
 
 
 
GMC  ranged  from  1166  U/mL  to 1964  U/mL,  and at Day 270 it ranged  from 530  U/mL  to  
910 
volunteers  had anti -rF1V levels  above the lower  limit of  quantification  (LLOQ)  of 10 U/mL.   
Theseroconversion  rates  and anti-rF1V  antibody  concentrations  within  the 4-week  period  after  
the thirdvaccination  were  statistically  similar  in all cohorts  studied  in the Phase  2a trial as well as 
in the Phase 2b  trial  
 
 
 
 
 
2.3.3.3  Phase  2b Clinical Trial,  rF1V -02b ([STUDY_ID_REMOVED])  
 
 
o 
t 
i c 2.3.3.2.1  Clinical Immunogenicity  Data  from  Phase  2a Cohort  3 (IND #12031)  
Note:  Group  = Cohort  

Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  26 of 79  
  
 
2.4 CpG  1018 Background  
2.4.1 CpG  1018 Mechanism  of Action  
CpG 1018 is a synthetic oligonucleotide containing immunostimulatory cytidine -phospho-  
guanosine (CpG) sequence motifs that mimic bacterial and viral DNA. CpG 1018 exerts its 
actions solely through a single, well -defined pattern recognition receptor in the innate immune 
system, Toll -like receptor 9 (TLR9), a mechanism that is distinct from other commercial 
adjuvants, including oil -in-water adjuvants. CpG 1018 efficiently induces dendritic cells to 
develop into highly effective antigen presenting cells. These activated dendritic cells drive the induction of helper T cells (Th) that are essential for the generation of antibodies and T and B cell memory  to vaccine antigens. CpG -1018 is particularly  effective  in stimulating  development 
of the Th1 subset of helper T cells, the Th subset that is essential for protection against most viruses  and intracellular bacteria.  Therefore,  the mechanism  of action  of the CpG  1018 adjuvant 
is well understood and highly specific. CpG 1018 specifically activates a key innate receptor, TLR9, and does not have demonstrable off -target activities.  
2.4.2 Review  of Available  Clinical Data  Supporting  Rationale  for CpG  1018 with  rF1V 
Antigen  
There are no clinical data available adding CpG 1018 to rF1V antigen. There are substantial safety  and immunogenicity data available  where  CpG 1018  has been  added to hepatitis  B surface 
antigen (HBsAg) in preventive vaccines and a growing database of CpG 1018 combined with SARS -CoV- 2 spike protein with and without alum. 
2.4.2.1  Summary  of Clinical Experience in  CpG  1018  
2.4.2.1.1 HEPLISAV -B (CpG 1018 + HBsAg)  
CpG 1018 3000 mcg with HBsAg has been evaluated in the clinical development program for HEPLISAV -B
®, approved by the US FDA on 9 November 2017 ( Dynavax Technologies 
Corporation 2020) and by the European Medicines Agency (EMA) on 18 February 2021 (Dynavax Technologies  Corporation 2021).  Data  are available  for 10,038 adult  subjects  between 
the ages of 18 and 70 years who received HEPLISAV -B in 3 phase 3 pivotal trials (HBV -10, 
HBV- 16, and HBV -23) and 8 additional supportive trials HBV0001, HBV -02, HBV -03, 
HBV- 04, HBV- 05, HBV- 08, HBV- 14, and HBV- 22. the antigen -only cohorts at either schedule. Moreover, the cohort that received the rF1V Plague 
Vaccine  on the Day 1-, 57-, 183-schedule  had statistically  higher  immune  response  after the third 
vaccination than the cohort that received vaccine on the Day 1, 57, 122 schedule. Vaccination 
with the rF1V Plague Vaccine was well -tolerated under both administration schedules. The 
majority of TEAEs were mild or moderate in severity, and the most frequently observed TEAEs 
were local reactions. The incidence of local and systemic reactions and other TEAEs did not 
increase with re -exposure to the vaccine during the study. No late -onset safety issues were 
apparent during 12 months of follow -up. 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  27 of 79  
 
In the HEPLISAV -B clinical  development  program  of over 14,000 subjects,  comparative  studies 
of 2 doses  of HEPLISAV -B (20 mcg HBsAg  + 3,000 mcg CpG 1018)  over 1 month  (Days  1 and 
29) with 3 doses of the alum adjuvanted Engerix- B® (20 mcg HBsAg + 500 mcg alum) over 6 
months (Days 1, 29, and 183) showed statistically significantly higher immunogenicity in 
HEPLISAV -B recipients than Engerix -B recipients with a similar safety and tolerability profile. 
Seroprotection rates (SPR; % with antibodies to hepatitis B surface antigen [anti- HBs] 2' l0 
mIU/mL) of more than 90% were produced in all populations studied and were statistically 
significantly higher than those induced by Engerix- B (Figure 2 -2). 
Figure 2 -2: Example  of Typical  Seroprotection  Rates  by Visit in  the Pivotal  Trials 
(Trial HBV -10 Per Protocol Population; 18 to 55 year old adults)  
 
(Halperin,  Ward  et al. 2012)  
PP = Per-protocol;  SPR = seroprotection  rate. 
Note:  The median  time to seroprotection  of the 2-dose HEPLISAV -B schedule  occurred  5 months  earlier  than the 
3-dose Engerix- B schedule, denoted by the red arrows. Similar time courses of seroprotection were observed in 
HBV -16 (Heyward, Kyle et al. 2013 ) and HBV -23 (Jackson, Lentino et al. 2018 ). 
 
In the Dynavax study HBV -10 of adults 18 to 55 years of age, the SPR at four weeks after the 
second dose of HEPLISAV -B, at week 8, was statistically significantly higher than the SPR in 
the Engerix- B group at week 8 (88.4% vs 26.7%, p < 0.0001). It was also significantly higher 
than the peak  SPR following  three  doses of Engerix- B at week  28 (81.3%, p < 0.001). At  week  8, 
the geometric mean concentration (GMC) of anti -HBs antibodies was 83.1 mIU/mL in the 
HEPLISAV -B group and 6.5 mIU/mL in the Engerix- B group (p < 0.0001). The peak GMC in 
the HEPLISAV -B group (341.6 mIU/mL) was similar to the peak GMC in the Engerix- B group 
(352.1 mIU/mL).  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  28 of 79  
 In summary, the CpG 1018 adjuvanted HBV vaccine, HEPLISAV -B, with a 2 -dose regimen 
administered  within  1 month induced a peak  SPR,  GMC, as  well as duration of response  greater 
than or similar to  what was seen after 3 doses of Engerix administered over 6 months. The 
improved dosing schedule achieved by adjuvating  HBsAg with CpG 1018 is comparable to the 
goal identified by the Military in this prototype project, namely accelerating the onset of 
protection and a non- inferior or superior immunological response to rF1V antigen in a 
dramatically shortened vaccination schedule.  
Safety data are available for 9365 adult participants who received CpG 1018 in the three phase 3 
HEPLISAV -B pivotal trials (HBV -23, HBV -16, and HBV -10) and 31,000 HEPLISAV -B recipients 
in a post-marketing  study.  In addition,  over 900,000 doses  of HEPLISAV-B  have  been  distributed in 
the US since 2017 with benign spontaneous safety reports both to the Vaccine Adverse Events Reporting System (VAERS) and Dynavax. 
HEPLISAV -B induces a similar frequency of local post -injection reactions (PIRs) and a lower 
frequency of systemic PIRs (including fever) compared to Engerix-B. Overall, 55.1% of subjects in 
the HEPLISAV -B arm experienced any PIR compared to 57.1% of subjects in the Engerix-B arm. 
Systemic PIRs occurred in 32.3% of the HEPLISAV -B group and 37.4% of the Engerix-B group, 
and local PIRs occurred in 42.8% of the HEPLISAV -B group and 41.1% of the Engerix-B group. 
Adverse events, serious adverse events, immune -mediated adverse events of special interest, and 
deaths were balanced between the HEPLISAV -B and Engerix- B groups. Changes in autoantibodies 
including ANA,  anti-dsDNA,  and ANCA  were similar  between  vaccine groups  (Hyer, McGuire  et al. 
2018).  
2.4.2.1.2 CpG  1018 as a Biological  Response Modifier  in Ongoing  Clinical and Preclinical 
Programs  
Dynavax is evaluating CpG 1018 in multiple clinical development programs. In all of these 
studies, CpG 1018 was combined with aluminum hydroxide (ie, alum, Alhydrogel® 2%) as the adjuvant. Preclinical studies in multiple animal models, and now humans, have shown substantially greater adjuvant activity of a combination of CpG 1018 and alum than with either of the individual adjuvants. Studies in non- human primates have demonstrated the 
immunogenicity  of two different SARS -CoV- 2 spike  protein  antigens  adjuvanted with CpG 1018 
and alum ( Arunachalam, Walls et al. 2021) (and unpublished data from NIH Vaccine Research 
Center). In the NIH study, monkeys were immunized twice with recombinant spike from the original Wuhan strain of SARS -CoV -2 and were fully protected when challenged 8 months later 
with the SARS -CoV- 2 beta variant, demonstrating the durability and breadth of the protective 
antibody response. Importantly, results from human studies with multiple COVID -19 vaccine 
antigens utilizing CpG -1018 and alum confirm the ability of this adjuvant formulation to 
stimulate high levels of IgG, neutralizing antibodies, and T cell responses with a 2- dose regimen 
with no safety concerns ( Hsieh, Liu et al. 2021, Richmond, Hatchuel et al. 2021) (Valneva and 
BiologicalE unpublished data).  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  29 of 79  
 Importantly, in two of the above studies, same day mixing of CpG -1018 with antigen and alum 
(Alhydrogel  2%) was  employed, and the resulting  mixture  given  as a single  injection  (Richmond, 
Hatchuel et al. 2021) (Valneva unpublished data). 
The two most advanced subunit COVID -19 vaccines provide substantial evidence of the 
effectiveness, tolerability, and safety of the combined CpG 1018 + alum (Alhydrogel  2%) 
adjuvant. The immunogenicity of MCV -COV1901, a COVID- 19 vaccine using the NIH SARS - 
CoV- 2 spike  protein  with 750 mcg of CpG 1018 and alum  was evaluated  in a phase  1, open- label 
dose-finding study. After the second vaccination with MCV -COV1901, the spike specific IgG 
titers increased with peak geometric mean titers of 7178 (low antigen dose), 7746 (middle  
antigen dose), and 11220 (high antigen dose) ( Hsieh, Liu et al. 2021). In addition, serum 
neutralizing activity geometric mean values were 1.8 to 3.9 times higher than those of a panel of 
control human convalescent sera. A phase 2 study of over 3800 participants > 19 years of age, randomized 6:1, has recently reported a geometric mean neutralization titer of 662, a GMT ratio of 163, and a seroconversion rate of 99.8% ( Hsieh, Liu et al. 2021).  These results meet the 
criteria established by the  Taiwan FDA for Emergency Use Authorization. The vaccine was well 
tolerated  with no severe adverse reactions. Injection  site pain (71.2%),  most  of mild severity, was 
the most frequent post -injection reaction. The most frequent systemic post -injection reactions 
were fatigue (MCV -COV1901: 36%; placebo: 29.7%), myalgia (MCV -COV1901: 27.6%; 
placebo: 16.6%), and headache (MCV -COV1901: 22.2%; placebo: 20%). Fever was uncommon 
(MCV- COV1901: 0.7%; placebo: 0.4%)  (Hsieh, Liu et al. 2021)  
The safety and immunogenicity of  the second COVID -19 vaccine, SCB -2019, were evaluated in 
a phase 1, randomized, double -blind, placebo -controlled dose -finding study in healthy adults 
(Richmond, Hatchuel et  al. 2021). SCB -2019 is a protein subunit vaccine candidate containing a 
stabilized trimeric form of the SARS -CoV- 2 spike protein (S -Trimer) combined with 1500 mcg 
of CpG 1018 and 750 mcg of alum. SCB- 2019 with no adjuvant elicited minimal immune 
responses, but adjuvanted SCB -2019 induced high titers  and seroconversion rates  of binding and 
neutralizing antibodies. IgG responses were observed at all dose levels after the first dose, but titers were greatly increased after the second dose, with GMTs of 478 –2440 on Day 36. High 
GMTs were maintained to Day 50, when seroconversion rates were 87.5 –93.8%. CpG 1018 + 
alum  titers  were  2.1-fold higher than those  recorded  in a panel  of convalescent  sera from patients 
with COVID- 19. SCB- 2019 elicited Th- 1-biased CD4+ T -cell responses.  
In a follow up analysis ( Richmond, Hatchuel et al. 2021), immunoglobulin G (IgG) antibodies 
were measured against SCB -2019, angiotensin- converting enzyme 2 (ACE2) competitive 
binding antibodies, and neutralizing  antibodies  against  wild-type SARS -CoV- 2 (Wuhan -Hu-1) at 
Days 101 and 184, and neutralizing antibodies against 3 VoCs, Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1), in Day 36 sera. Titers waned from their peak at Days 36–50, but SCB -2019 
IgG antibodies, ACE2 competitive binding antibodies, and neutralizing antibodies against wild-  
type SARS -CoV- 2 persisted at 25% –35% of their observed peak levels at Day 184. Day 36 sera 
also demonstrated dose -dependent increases in neutralizing titers against the 3 VoCs. 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  30 of 79  
 2
 The vaccine was well tolerated  with no severe adverse reactions. Injection  site pain (62.5), most 
of mild severity,  was the most  frequent  post-injection  reaction.  The only systemic post-injection 
reactions were headache (SCB- 2019: 25.0%; placebo: 14.3) and fatigue (SCB -2019: 12.5%; 
placebo: 0).  
Based on a model by Khoury and colleagues (Khoury, Cromer et  al. 2021),  both vaccines, with a 
ratio of neutralizing antibodies  to antibodies  in human convalescent  sera greater than  2, are likely 
to have an efficacy against COVID -19 greater than 85% to 90%. 
2.5 Study  Rationale and Doses  to Be Evaluated  
Dynavax will conduct an adaptive clinical trial to determine if CpG 1018, the adjuvant used in 
HEPLISAV -B, can be utilized as a Biological Response Modifier (BRM) to improve the 
operational utility of the current investigational rF1V vaccine for the Military without re - 
formulation of the  adjuvant. Dynavax will evaluate  both coadministration  (rF1V and CpG 1018 
administered in two concurrent injections in the same location), and a bedside mix (rF1V and 
CpG 1018 combined in a single syringe prior to vaccination) compared to rF1V alone to determine  the method of administration  that provides  an acceptable immune  response  conducive 
to field deployment. A two- dose schedule at Day 1 and Day 29 will be tested which would 
enhance military rapid -response capabilities afforded by the investigational rF1V vaccine.  
Dynavax has designed the trial to be powered to support the current rF1V pre -Emergency Use 
Authorization. Completion of the proposed prototype project will support the development of 
next generation rF1V  vaccine(s) with  an enhanced operational  utility  for the military  and for the 
prevention and/or curtailment of a pneumonic plague outbreak. 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  31 of 79  
 Bridge  ELISA  
Bridg
 ELIS
 
5
 (Week  8) 
211 (Week  30) 3 STUDY OBJECTIVES AND  ENDPOINTS  
The study objectives  and endpoints  are: 
 
Objectives  Endpoints  
PART 1 
Primary  
• To select one of the two methods of 
administration of rF1V vaccine with CpG 1018 for Part 2 by comparing humoral  immunization  response  28 days 
after the second dose of vaccine  • Ratio of geometric mean ELISA 
concentration (GMC) between rF1V vaccine  with CpG 1018 and rF1V  vaccine  
Secondary  
• To assess the safety and tolerability of 
rF1V  vaccine with CpG 1018 compared 
with rF1V vaccine  • Rate of reactogenicity:  solicited  local  and 
systemic post -injection reactions  
• Rate of adverse  events (AEs),  severe  AEs, 
serious adverse events (SAEs), immune - 
mediated  adverse events of special  interest 
(AESI), and deaths  
PART  2 
Primary  
• To assess the utility of a 2 -dose 
schedule of rF1V vaccine with CpG 
1018 as measured  by reduction  in time 
to onset of predicted rF1V protection  • Predicted protection (percentage of subjects reaching the Bridge ELISA threshold that corresponds to 50% predicted  vaccine  efficacy)  after 2 doses of 
rF1V vaccine with CpG  1018 compared to 
that of 3 doses of rF1V vaccine  
Criterion for evaluation : Similar 
percentage of subjects  reaching the Bridge 
ELISA threshold that corresponds to 50% predicted vaccine efficacy after 2 doses of rF1V vaccine with CpG 1018 at Day 57 (Week  8) compared  to that after 3 doses of 
rF1V vaccine at Day 211 (Week 30)  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  32 of 79  
 Bridge  ELISA  
Bridge  
 
Bridge  ELISA  
Bridge  ELISA  57 (Week 8) 
Week  0/baseline: prior  to the first 
injection  
Week  4: prior  to the second  injection:  1 
month  after the first injection  for each 
vaccine  group.  
Week  
 4 weeks  after the 
 injection  for each vaccine group  
Week  12: 8 weeks  after the 
 injection  for each vaccine group  
Week  16: 12 weeks  after the 
 injection  for each vaccine group  
Week  30: 28 days ( 4 weeks  ) after 
 ird 
injection  for Group  3 / 26 weeks  after 
second  dose of CpG  1018  vaccine  for 
Groups  1 or 2  
• To assess the serum Bridge ELISA 
antibody concentration to rF1V with 
CpG 1018 compared with rF1V  vaccine 
28 days after the second dose of vaccine • Ratio of geometric mean ELISA 
concentration (GMC) between rF1V 
vaccine  with CpG 1018 and rF1V  vaccine 
28 days after the second dose  
Criterion  for evaluation : 2-times  increase 
in Bridge  ELISA  GMC point  estimate  after 
the second  dose of rF1V  vaccine with CpG 
1018 to that after the second dose of rF1V vaccine at Day 57 (Week 8)  
Secondary  
• To assess the safety and tolerability of rF1V  vaccine with CpG 1018 compared 
with rF1V vaccine  • Rate of reactogenicity:  solicited  local  and 
systemic post -injection reactions  
• Rate of AEs,  severe AEs,  SAEs,  AESIs, 
and deaths  
• To assess the serum Bridge ELISA 
concentration  to rF1V  with CpG 1018 at 
selected time points after each dose  • GMC and seroconversion rate of serum 
rF1V  titers  at the following 
selected time points after each dose of 
vaccine:  
• Week  0/baseline:  prior to the first 
injection  
• 
month after the first injection  for each 
vaccine group. 
• Week  8: 4 weeks after the second 
injection for each vaccine group  
• Week  12: 8 weeks after the second 
injection for each vaccine group  
• Week  16: 12 weeks after the second 
injection for each vaccine group  
• Week  30: 28 days  (4 weeks)  after third 
 
second  dose of CpG 1018 vaccine for 
Groups 1 or 2 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  33 of 79  
 Exploratory  
 
• To assess long term clinical benefit from  • Risk ratio of subjects with 2' 6 months 
rF1V vaccine with CpG 1018 compared   clinical  benefit between  rF1V  vaccine  with 
with rF1V vaccine   CpG 1018 and rF1V vaccine  
Criterion for evaluation : 2' 6 months 
clinical benefit is defined as retaining the 
predicted protection antibody level at 6 months after the complete series. Previous rF1V vaccine data showed a small percentage of subjects who received 3 doses of rF1V vaccine had 2' 6 months clinical  benefit.  Similar  levels are 
expected 
for those who received rF1V vaccine with CpG 1018 at Day 197 (Week 30).  
• To assess the utility of a 2 -dose • Predicted protection using peak serum 
schedule of rF1V vaccine with CpG   rF1V  Bridge  ELISA  concentration  after 2 
1018 as measured by reduction in time   doses of rF1V vaccine with CpG 1018 
to onset of predicted rF1V  compared  to that at 28 days after 3 doses of 
protection using peak serum Bridge  rF1V vaccine 
ELISA concentration   Criterion for evaluation : Similar 
percentage  of subjects  reaching  the Bridge  Week  38: 84 days ( 12 weeks  ) after the 
third  injection  for Group  3 / 34 weeks  
after the second  injection  for Groups  1 
or 
 Week  50: 168 days  ( 24 weeks  ) after the 
third  injection  for Group  3 / 46 weeks  
after the second  injection  for Group  1 
or 
 • Week  38: 84 days (12 weeks  
third injection for Group 3 / 34 weeks 
after the second  injection  for Groups  1 
or 2 
•  
 
 
 
Seroconversion is defined as the presence 
of detectable antibody in subjects who had 
no detectable antibody levels at Day 1, or a 
2' 2-fold increase in antibody level in 
subjects who had detectable antibody 
levels at Day 1.  
Criterion for evaluation : GMC and 
seroconversion rate point  estimates  from 
rF1V vaccine with CpG  1018 to meet or 
exceed results from rF1V vaccine at 
relevant visits  Week  50: 168 days  (24 weeks  
third  injection  for Group  3 / 46 weeks   
after the second  injection  for Group  1 
or 2  
 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  34 of 79  
  
ELISA threshold that  corresponds  to 50% 
predicted  vaccine efficacy  after 2 doses of 
rF1V vaccine with CpG 1018 at peak 
(Days 57, 85, 113 / Weeks 8, 12, 16) as 
compared to that after 3 doses of rF1V 
vaccine at Day 211 (Week 30)  
 
 
• To assess the peak serum bridge  • Ratio  of GMCs  and seroconversion rates 
ELISA concentration from rF1V with   between rF1V Bridge ELISA serum  CpG 1018 compared with rF1V concentration  at peak  in rF1V  vaccine with 
vaccine 28 days after the complete  CpG 1018 group and at 28 days in rF1V 
series vaccine group after the complete series  
Criterion  for evaluation : Similar GMC 
and seroconversion rate after 2 doses of 
rF1V vaccine with CpG 1018 at peak 
(Days 57, 85, 113 / Weeks 8, 12, 16) as 
compared to that after 3 doses of rF1V 
vaccine at Day 211 (Week 30)  
• To assess the serum Bridge ELISA 
concentration  to rF1, and rV with CpG 
1018 at selected time points after each 
dose • GMC and seroconversion rate of serum 
rF1, and rV Bridge ELISA titers at the 
following  selected  time points after each 
dose of vaccine:  
• Week  0/baseline:  prior to the first 
injection  
• Week  4: prior  to the second injection: 4 
weeks after the first injection for each 
vaccine group. 
• Week  8: 4 weeks after the second 
injection for each vaccine group  
• Week  12: 8 weeks after the second 
injection for each vaccine group  
• Week  16: 12 weeks after the second 
injection for each vaccine group  
• Week  30: 4 weeks after third  injection 
for Group 3 / 26 weeks after second 
dose of CpG 1018 vaccine for Groups 
1 or 2 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  35 of 79  
  
  • Week 38: 12 weeks after the third 
injection for  Group 3 / 34 weeks after 
the second  injection  for Groups 1 or 2  
• Week 50: 24 weeks after the third 
injection  for Group 3 / 46 weeks after 
the second injection for Group 1 or 2 
• Seroconversion is defined as the 
presence of detectable antibody in 
subjects who had no detectable 
antibody levels at Day l, or a 2' 2- fold 
increase in antibody level in subjects 
who had detectable antibody levels at 
Day 1  
• Criterion for evaluation: GMC and 
seroconversion rate point estimates 
from rF1V  vaccine  with CpG 1018 to 
meet or exceed results from rF1V 
vaccine at relevant visits   
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  36 of 79  
 1, 29,  and 183 and 29 (and  placebo at Day 183 
1 and  
 and 2 injections  of placebo  will be administered on 
Day 183 
1 and 
 and 
2 separate  injections  of placebo  will be administered  on Day 183 
1
 29, and 183 
1 and 
and 2 injections  of placebo  will be administered  on 
and 
1, 29,  and 183. 
and (and placebo at  Day 183) 4 INVESTIGATIONAL  PLAN 
4.1 Study  Design  
This is a phase 2, randomized, active-controlled, observer- blinded, multicenter trial of the 
immunogenicity, safety, and tolerability of rF1V vaccine with CpG 1018 compared with rF1V 
vaccine alone  in adults. Approximately two hundred healthy adults 18 to 55 years of age  will be 
enrolled to compare a two -dose regimen of rF1V with CpG 1018 administered on study Days 1 
with a three -dose regimen  of rF1V  vaccine alone administered  
on study Days  
The study will be conducted in 2 parts (Part 1 and Part 2). The table below outlines study drug administration in both parts. When investigational product is co -administered as 2 separate 
injections, the  injections  should be administered  in close  physical proximity  to each other (within 
approximately 1 inch).  
Injections  will be administered  by study  personnel not otherwise involved in the subjects’  safety 
evaluation. Recording and evaluation of safety information and laboratory data will be 
performed by observers blinded to the subjects’ treatment assignment.  
Part  1: 
There  will be 2 methods of rF1V vaccine with CpG  1018 administration:  
• Group 1 (N = approximately 20): rF1V  vaccine and CpG 1018 will be co-administered  as 2 
separate injections on Days ;  
 
• Group 2 (N = approximately 20): bedside mix of rF1V  vaccine + CpG 1018 (administered  as 
1 injection) and placebo will be administered as 2  separate injections on Days 1 and 29;  
 
In addition, rFIV  vaccine will be administered  alone without CpG 1018:  
• Group 3 (N=20): rF1V  and placebo  will be administered  as 2 separate injections  on Days  
 
All Groups will receive 2 injections  at each treatment  visit to maintain  the blind.  
A Data  Monitoring Committee  (DMC)  will review  safety for  Part 1 after the first dose:  
• 72 hours after first dose in the first 6 subjects  
• 14 days after first dose in  the first 18  subjects  Day 183. 
29, and  183. 1, 2 separate  injections  of placebo  will be administered  on Day 183 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  37 of 79  
 5
 In addition, the  DMC may review  safety  data as needed  at any time during the study (as defined 
in the DMC charter).  
The administration  method of vaccine utilized in  Part 2 of the  study will be  selected by Dynavax 
in consultation with the DoD after Day 57 immunogenicity data become available to determine 
whether the GMC 1 month after 2 doses of rF1V vaccine with CpG 1018 using the selected administration  method is at least 2 times  higher than the 4 weeks after 2 doses of rF1V  vaccine in 
Group 3. Prior to enrolling  subjects in Part  2, the  Pharmacy Manual will be updated  to document 
the method of administration of rF1V vaccine and CpG 1018 selected for Part 2.  
• Part 2:  Part 2 will begin after immunogenicity assessments from the Day 57 visit in Part 1 
are completed.  The method of vaccine  administration  method  that is selected  from Part 1 will 
be evaluated in Part 2. Group 1 (if selected) (N=70): rF1V vaccine co -administered with  
CpG 1018  
• Group 3 (N=70):  rF1V  vaccine co-administered  with placebo  
OR 
• Group 2 (if selected)  (N = 70): bedside  mix of  rF1V  vaccine and CpG 1018  
• Group 3 (N=70):  rF1V  vaccine  
Subjects  will be followed  through Day 393 (Week  56) 
4.2 Study  Duration  
The total duration of participation in  the Screening, Treatment,  and Follow -up parts  of this  study 
is up to approximately 60 weeks. This  includes  a Screening  period  beginning up to 4 weeks prior 
to the first study injection and End of Study (EOS) visit 56 weeks after the first study injection.  
4.3 Randomization  and Blinding  
This is an observer -blinded clinical study. Both the study subjects and the study personnel 
involved in safety  assessment  (observers)  will be blinded to treatment  assignments.  Designated 
unblinded study- site personnel will be responsible for preparing and administering the study 
injection.  
In Part 1, subjects will be randomized 1:1:1 to Group 1, 2, or 3. In Part 2, subjects will be 
randomized 1:1 to 1 of 2 groups  (ie, either Group  1 and 3 or Group 2 and 3) as determined  from 
Part 1. Randomization will be stratified by site.  
4.4 Appropriateness of Measurements  
The measures of both immunogenicity and safety  in the  study  are routine  clinical  and laboratory 
procedures. Antibody response to rF1V must be above the assay defined cut -offs to be 
considered seropositive.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  38 of 79  
 The secondary and exploratory  evaluation  of immunologic  responses is based  on recently 
developed and validated assays appropriate for use on serum that will provide deeper 
understanding of the quality of the immune response induced by rF1V and CpG 1018. 
 
5 SELECTION OF SUBJECTS  
5.1 Inclusion  Criteria  
A subject  must  meet  all the following  criteria  to be eligible  for enrollment  (defined  as receiving 
any study vaccine) in the study:  
1) Adults  aged 18 to 55 years  
2) Healthy  subjects or  subjects with  pre-existing medical  conditions  who  are in a stable medical 
condition.  
Pre-existing stable medical condition means a subject who within 3 months prior to Day 1: 
has full capacity of  daily activity  and no major medication modification; has not undergone 
surgical  or minimally -invasive intervention or  had any hospitalization/emergency  room  visit 
for the specific medical condition.  
3) Able  to comply with the protocol  schedule and procedures.  
4) Able  and willing  to provide  written  informed  consent  
5) If female of child -bearing potential and heterosexually active, has practiced adequate 
contraception for  28 days prior to vaccination and has negative pregnancy tests just prior  to 
vaccination and has agreed to continue  adequate  contraception until 28 days after  last study 
injection. Adequate  contraception  is defined as a contraceptive  method with a failure  rate of 
< 1% per  year when used consistently  and correctly  and, when applicable, in  accordance with 
the product label. Examples include the following:  
• Combined (estrogen  and progestogen containing)  hormonal  contraception  associated  with 
inhibition of ovulation: oral, intravaginal, or transdermal  
• Progestin -only hormonal  contraception associated  with inhibition of ovulation:  oral, 
injectable, or implantable  
• Intrauterine  device  (IUD)  with or without  hormonal  release 
• Vasectomized  partner, provided he is the subject’s  sole partner and  that he has received  a 
medical assessment of the surgical success  
• Credible  self-reported  history  of heterosexual  abstinence  for at least 28 days prior to 
vaccine administration  
• Female partner  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  39 of 79  
 5.2 Exclusion  Criteria  
A subject  with any 1 of the following  criteria  is not eligible  for enrollment  (defined  as receiving 
any study vaccine) in the study:  
1) A history  of plague  disease  or have  previously received  any plague  vaccine.  
2) Active  tuberculosis  or other  systemic  infectious  process.  
3) History  of human immunodeficiency  virus  (HIV),  hepatitis  B (HBV) or  hepatitis  C (HCV) 
infection, or positive test for antibody to HIV, HBV, or HCV  
4) History  of autoimmune  disorder  (Appendix 3) 
5) History  of sensitivity  to any component  of study vaccines  
6) Body mass index 2' 30 kg/m2 
7) Has received  the following prior to the injection: 
• :: 14 days:  
• Any licensed  COVID- 19 vaccine  or any inactivated  vaccines (including vaccines 
containing mRNA or CpG)  
• :: 28 days:  
• Any live vaccine 
• Systemic corticosteroids (more  than 3 consecutive  days) or other  immunomodulators 
or immunomodulators  immune  suppressive medication, with the exception  of inhaled 
steroids  
• Any other  investigational  medicinal  agent  
• :: 90 days:  
• Antisense oligonucleotides  
• Granulocyte  or granulocyte -macrophage  colony- stimulating  factor  
• Immunoglobulins  or any blood products  
• Drugs/investigational  agents  with very long half-lives  (defined  as 2' 60 days)  
• At any  time: DNA plasmids  or other genetic  therapy intended to integrate  permanently 
into host cells 
8) If female  is pregnant  (known before  or established  at the time of screening), breastfeeding, or 
planning a pregnancy  
9) Is undergoing chemotherapy or expected  to receive chemotherapy during the study period; 
has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell 
carcinoma of the skin  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  40 of 79  
 10) History or current evidence of any condition, therapy, or laboratory abnormality that might 
confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the  subject  to participate,  in the opinion 
of the treating investigator 
11) Oral temperature  >100.0°F at  the time of vaccine  administration.  
12) History  of acute  myocardial  infarction  (AMI) or documented coronary artery  disease  (CAD)  
 
5.3 Criteria  for Discontinuation  of Individual  Subjects  From  Receiving 
Additional Study Injections  
The investigator will discontinue  dosing of an individual  subject  and notify the sponsor  within 
24 hours if the subject experiences an AE including any of the following:  
• Grade  4 post-injection  reaction  (PIR)  within  7 days after any  study injection  
• Clinically  significant  Grade  3 or higher  systemic  reaction  (eg, angioedema, generalized 
urticaria) within 7 days after any study injection  
• Grade  3 or 4 hypotension within  24 hours  of any study injection  
• Grade  3 or 4 respiratory  reaction  or symptoms  occurring within  24 hours  of any study 
injection  
• Any life-threatening  AE, regardless of relationship  to study  drug 
• Any AMI  
• Any confirmed  immune -mediated  AE 
• Violation  of protocol eligibility  criteria  
• Subject  received  prohibited medications  
• SAE assessed  as a suspected  adverse  reaction  (SAR) or adverse  reaction  (AR)  
• Subject  becomes  pregnant  or begins  breastfeeding  
If the  subject  is not eligible  for subsequent  study injections, the subject will not be withdrawn 
from the study , but, if possible, will be  followed  for safety through End-of-Study (EOS) Visit.  
5.4 Removal  of Subjects  From  the Study  
Subjects  may choose  to withdraw  from  the study  at any time.  The reason  for withdrawal will be 
recorded on the case report form (CRF).  
Subjects  may also be discontinued from  the study  by the investigator  for any of the following 
reasons:  
• Subject  does not receive a dose of study  vaccine  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  41 of 79  
 • Noncompliance with study  procedures as determined  by the investigator or sponsor  
• At the discretion  of the  investigator if it is felt to no longer be in the best interest  of the 
subject to remain in the study  
• The sponsor decides to terminate  the study  
The investigator or designee should discuss with the medical  monitor prior  to withdrawing  a 
subject from the study before study completion.  
• If a subject discontinues, the End of Study (EOS) assessments should be completed. 
Required procedures are listed  in Section  9.7 and in the Schedule of Events ( Appendix 1).  
• Additional information about  terminating  the study may be found in Section 6 . 
 
5.5 Replacement of  Subjects  
Subjects randomized  and not treated  may be replaced  at the discretion  of the Dynavax medical 
monitor.  
5.6 Study  Termination  
The sponsor reserves the right to terminate  the study at any time. Reasons  for discontinuation of 
the study include but are not limited to:  
• Inability  to enroll sufficient  subjects into the study  
• Good clinical practice (GCP)  compliance issues that compromise  the validity  of the study 
• Emerging  safety  or efficacy  data that deem  the study unethical or impractical  for 
continuation  
Procedures for withdrawal  of individual subjects can be found in Section  5.3. 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  42 of 79  
 6 STUDY TREATMENT  AND SUPPLIES  
6.1 Study  Treatments  
6.1.1 rFIV  Vaccine  
rFIV  vaccine is comprised  of Y. pestis  plague  recombinant  antigen (F1 capsular protein  and the 
V virulence protein of Y. pestis Colorado 92 [CO92] fused into a single protein) adsorbed to 
Alhydrogel® (aluminum hydroxide). 
The rF1V  Plague  Vaccine is a liquid  formulation,  containing no preservatives, in  3 mL, single 
dose USP Type 1 glass vials with a latex -free butyl stopper and aluminum flip -off seal 
containing 0.8 mL of the vaccine, and each dose of 0.5 mL contains 160 mcg rF1V, 750 mcg 
aluminum hydroxide (alum, Alhydrogel®) and phosphate buffer.  
Please refer  to the Investigator’s  Brochure  and Pharmacy Manual for  additional  information.  
6.1.2 CpG  1018  
CpG 1018 adjuvant  solution  (12 mg/mL) is  a clear  to slightly  opalescent, colorless to pale yellow 
liquid dosage form. CpG 1018 is formulated in 20 mM Tris, 100 mM NaCl pH 7.5 buffer. Each 
vial contains 6 mg of CpG 1018 formulated in 0.5 mL at a concentration of 12 mg/mL in a  
single -use 2 mL, clear  glass vial with rubber  stopper  and flip-off aluminum seal. 
Please refer to  the rF1V  Vaccine with CpG 1018  Investigator’s  Brochure  for additional 
information.  
6.1.3 Placebo  
Placebo  will be  normal saline.  
6.2 Instructions for Preparation  and Administration  
6.2.1 rFIV  vaccine  and CpG  1018 Preparation  
Please refer  to the Pharmacy  Manual  for additional  information.  
6.2.2 Study  Vaccine  Administration  
Designated unblinded study- site personnel will be responsible for preparing and administering 
the study injection. These individuals will  not be  blinded to the  treatment assignment in  order  to 
prepare and administer the study injections, which will be prepared at a location isolated from blinded personnel. These  individuals  will not be involved in assessing  safety  and laboratory  data 
and will be instructed not to communicate treatment assignments to blinded study personnel.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  43 of 79  
 and 
 , and 2  injections  of 0.25 mL placebo will be  administered on Day  183 
and 
 , and 2  injections  of 0.25 mL placebo will  be administered  
o
 Day 183 
9
 , 
 and 
183 
and and 2 injections  of 0.25 mL placebo  will be administered o n Day 183 
9
 , 
 and 
183. 
183 
9
 , 2 and 183. and 2
 
1 9, 
1 and 2 9, and 2  injections  of 0.25 mL placebo  will be administered  
1 and 29,  and 2  injections  of 0.25 mL placebo  will be  administered o   Day 183. 
1, 29 and 
183. 
1 and 29, The unblinded study personnel should ensure that a physical barrier  is used to obstruct the view 
of the investigational product and that the subject turns their head away from the arm being 
injected to prevent the subject becoming aware of their treatment assignment.  
6.2.2.1  Part  1 
Group 1: 0.5 mL of rF1V vaccine and 0.25 mL of CpG 1018 will be administered 
intramuscularly  in the same  or nearby location of the deltoid  muscle of the non-dominant arm on 
Days  . 
Group 2: 0.75 mL of the bedside mix of rF1V vaccine and CpG 1018 and 0.25 mL of placebo 
will be administered  intramuscularly  in the same or nearby location  of the deltoid  muscle  of the 
non-dominant arm on Days  
 
Group 3: 0.5 mL of rF1V  vaccine and 0.25 mL of placebo  will be administered  intramuscularly 
in the same or nearby location of the deltoid muscle of the non -dominant arm on Days  
 
6.2.2.2  Part  2 
Scenario  1: Group 1 is selected.  
Group 1: 0.5 mL of rF1V vaccine and 0.25 mL of CpG 1018 will be administered 
intramuscularly  in the same  or nearby location of the deltoid  muscle of the non-dominant arm on 
Days  
Group 3: 0.5 mL of rF1V  vaccine and 0.25 mL of placebo  will be administered  intramuscularly 
in the same or nearby location of the deltoid muscle of the non-dominant arm on Days  
 
Scenario  2: Group 2 is selected.  
Group 2: 0.75 mL of the bedside mix of rF1V vaccine and CpG 1018 will be administered 
intramuscularly in the deltoid muscle of the non-dominant arm on Days and 0.25 mL 
placebo will be administered on Day  
Group 3: 0.5 mL of rF1V  vaccine will be administered  intramuscularly  in the same or nearby 
location of the deltoid muscle of the non-dominant arm on Days  
Study treatments  are presented  in Table  7-1. 
6.3 Labeling  
rF1V  vaccine and CpG 1018 adjuvant solution will be provided for the study  and labeled  for 
clinical study use.  
Day 183. 
1, 29 and 
183. 
183. 
1 29  and 183 
 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  44 of 79  
 At a minimum, both  rF1V  vaccine and CpG  1018 adjuvant  solution will  be labeled  with  the 
following information: product name, product lot  number, contents, volume, concentration, 
sponsor name, and a statement indicating that the drug is for investigational use only.  
6.4 Storage and  Handling  Instructions  
The clinical supplies storage area at the site must be monitored closely by the designated site 
staff for temperature consistency and documentation of temperature monitoring must be 
maintained. Temperature excursions outside of the recommended storage range may impact 
product  quality and must  be reported to Dynavax or its  designee  per the detailed  instructions  in 
the Pharmacy Manual.  
6.4.1 rF1V  and CpG  1018  
Both  rF1V  vaccine and CpG 1018 must  be kept under refrigeration  (2°C  to 8°C). After 
preparation of drug product, it must be used within 6 hours.  
Do not freeze. If product  is frozen, do not use. A Pharmacy  Manual  will be provided with 
specific instructions for management of temperature excursions.  
6.4.2 Bedside  mix of rF1V  vaccine and CpG  1018  
Please refer  to the Pharmacy  Manual for  additional  information.  
7 TREATMENT OF SUBJECTS  
7.1 Study  Treatments  
Study treatments  are presented  in Table  7-1. For each  dose, injections  are to be administered  in 
the order specified in the table.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5  
 CONFIDENTIAL  Part  1 
Dose  1 (Day  Dose  2 (Day  2 Dose  3 ( Day 183 
Group  1 rF1V  vaccine  and CpG  1018  coadministration  
Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.25 mL placebo  
Injection  2 0.25 
 CpG 1018  0.25 
 CpG 1018  0.25 mL placebo  
Tota
 0.75 
 0.75 
 0.5 
 Group  2 rF1V  vaccin
 + CpG  1018  bedside  mix 
Injection  1 0.75 mL rF1V+1018  0.75 mL rF1V+1018  0.25 mL placebo  
Injection  2 0.25 mL placebo  0.25 mL placebo  0.25 mL placebo  
Tota
 1.0 
 1.0 
 0.5 
 Group  3 rF1V vaccine  
Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  
Injection  2 0.25 mL placebo  0.25 mL placebo  0.25 mL placebo  
Tota
 0.75 
 0.75 
 0.75 
 Part  2 
Dose  1 (Day  Dose  2 (Day  2 Dose  3 ( Day 183 
Group  1 rF1V  vaccine  and CpG  1018  coadministration  
Scenario  1 Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.25 mL placebo  
(Group  1 and 3) Injection  2 0.25 
 CpG 1018  0.25 
 CpG 1018  0.25 mL placebo  
Tota
 0.75 
 0.75 
 0.5 
 Group  3 rF1V vaccine  
Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  
Injection  2 0.25 mL placebo  0.25 mL placebo  0.25 mL placebo  
Tota
 0.75 
 0.75 
 0.75 
 OR 
Scenario  2 Group  2 rF1V  vaccine  + CpG  1018  bedside  mix 
(Group  2 and 3) Injection  0.75 mL rF1V+1018  0.75 mL rF1V+1018  0.25 mL placebo  
Group  3 rF1V vaccine  
Injection  0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  
0.5 mL of rF1V  vaccine  = 160 mcg rF1V  + 750 mcg alum  
0.25 mL of CpG  1018  = 3000  mcg 
, Day 9, and Day 183 
Table 7 -1: Study  Treatments  
 
Part  1 
y 1) 9) 3) 
Group  1 rF1V  vaccine  and CpG  1018  coadministration  
0.5 mL rF1V  0.5 mL rF1V  
Injection  2 
Total  0.25 mL CpG  1018 0.25 mL CpG 1018 0.25 mL placebo  
0.75 mL 0.75 mL 0.5 mL 
Group  2 rF1V vaccine  CpG  1018  bedside  mix 
0.75 mL rF1V+1018  0.75 mL rF1V+1018  
Injection  2 0.25 mL placebo  0.25 mL placebo  0.25 mL placebo  
Total  1.0 mL 1.0 mL 0.5 mL 
Group  3 rF1V vaccine  
0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  
Injection  2 0.25 mL placebo  0.25 mL placebo  0.25 mL placebo  
Total  0.75 mL 0.75 mL 0.75 mL 
Part  2 
Dose 1 (Day 1) Dose 2 (Day 29)  Dose 3 (Day  183) 
Group 1 rF1Vvaccine and CpG 1018 coadministration  
Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.25 mL placebo  
Injection  2 0.25 mL CpG 1018 0.25 mL CpG 1018 0.25 mL placebo  
Total  0.75 mL 0.75 mL 0.5 mL 
Group  3 rF1V vaccine  
Injection  1 0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  
 
  
 
Scenario  2 
(Group  2 and 3) Injection  2 0.25 mL placebo  0.25 mL placebo  0.25 mL placebo  
Total  0.75
  mL 0.75 mL 0.75 mL 
OR 
Group  2 rF1Vvaccine  + CpG  1018 bedside  mix 
Injection  0.75 mL rF1V+1018  0.75 mL rF1V+1018  0.25 mL placebo  
Group  3 rF1V vaccine  
Injection  0.5 mL rF1V  0.5 mL rF1V  0.5 mL rF1V  
 
0.25 mL of CpG 1018  = 3000 mcg 
 
7.2 Dosage and Dosage Regimen  
Subjects will receive their assigned  vaccine on Day 
7.3 Treatment  Compliance  
All study injections  will be administered  by the designated unblinded study  personnel only.  
 
 
 
 
 
AND  PROPRIETARY  Page  45 of 79 
1, Day 29, and Day  183. Scenario  1 
CONFIDENTIAL  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  46 of 79  
 7.4 Control  and Accountability  of Investigational  Medicinal  Product  
All investigational medicinal product (IMP) must be received by a trained designated person at 
the study site, handled and stored  safely  and properly, and kept in a secured  location with limited 
access.  
The investigator (or responsible designee) must maintain current and accurate records of the 
receipt  (documentation from  shipments  of study treatments  received),  administration  (by subject 
and overall accounting) and return of study treatments to a Dynavax- specified facility for 
destruction (or destroyed by procedures approved by Dynavax). All study treatments must be stored in a location with access restricted to authorized personnel only.  
A study monitor  will be responsible  for monitoring  the drug accountability  at the site. The study 
monitor should be contacted with any questions concerning administration of study treatments.  
Records  of study treatment accountability, storage,  and handling must  be made  available  to the 
study monitor for the purposes of study treatments accountability. Any discrepancy and/or deficiency must be recorded with an explanation. 
Unless superseded by Standard Operating Procedures (SOPs), the investigator must retain all 
used vials, expired vials,  damaged  vials, and  unused vials  of study vaccine until accountability 
has been confirmed by the study monitor. Any exceptions to this policy must be specifically granted by Dynavax or its designee.  
At the end of the  study, or upon request  by Dynavax, all  used, partially  used, and unused study 
treatments must be destroyed by procedures approved by Dynavax or returned to a Dynavax-  
specified facility for adequate disposition.  
Refer to  the Pharmacy  Manual  for detailed  instructions  on handling, control, and accountability 
of study vaccine.  
Study vaccine  may not be used for any purpose  other than that described  in this protocol.  
7.5 Concomitant Medications  
7.5.1 Prohibited Treatments  or Therapies  
The following non-study  medications  are prohibited:  
• Any licensed  COVID- 19 vaccine  or inactivated  vaccine  (including  vaccines containing 
mRNA or CpG)  
• :S 14 days prior  to each study injection  through 14 days after each study injection  
• Any live  vaccine  
• :S 28 days prior  to each study injection  through 28 days after each study injection  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  47 of 79  
 • Other  concomitant  medications  
• :S 28 days prior  to vaccine  injection  (Day  1) through  28 days after the third  study vaccine 
injection Week 26 (Day 183):  
• Systemic corticosteroids (more  than 3 consecutive  days) or other  immunomodulators 
or immunomodulators  immune  suppressive medication, with the exception  of inhaled 
steroids  
• Any other  investigational  medicinal  agent  
• :S 90 days prior to vaccine injection  (Day  1) and through 28 days after the third  study 
vaccine injection Week 26 (Day 183):  
• Granulocyte  or granulocyte -macrophage  colony- stimulating  factor  
• Immunoglobulins  or any blood products  
• Antisense oligonucleotides  
• Drugs/investigational  agents  with very long half-lives  (defined  as 2' 60 days)  
• At any time prior  to vaccine  injection  (Day  1) and through 28 days after the  third  study 
vaccine injection Week 26 (Day 183):  
• DNA plasmids  or other  genetic therapy intended to integrate  permanently  into host 
cells 
 
If a subject  requires  treatment  that is prohibited, the subject will not be withdrawn  from  the 
study but will be followed for safety through Week 56. 
7.5.2 Permitted  Therapy  
Use of any permitted  medications, including over-the-counter  medications  or vaccine(s)  during 
the 28 days prior to the first study vaccine injection through Week 56 or Early 
Discontinuation/EOS Visit, should be solicited from each subject and recorded in source documents. Use of vitamins  and dietary supplements  will not be collected. Medications started 
prior to dosing, and any medication used within the 28 days prior to dosing will be recorded.  
All collected concomitant medications will be recorded in the  CRF.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  48 of 79  
 8 MANAGEMENT OF SUBJECT  SAFETY 
8.1 Data  Monitoring  Committee  
The Sponsor will  establish  a DMC for this study. The DMC members  and procedures  will be 
described in the DMC charter.  
8.2 Potential Reasons  for Stopping  the Study  
Dosing of all  subjects  will be temporarily  stopped for any of the  following: 
• Two or more subjects with Grade 3 (severe) or higher severity solicited adverse reactions 
(considered by the sponsor to be possibly or probably  related  to treatment)  lasting  more  than 
48 hours AND considered by the DMC to be clinically significant  
• Two or more  subjects  who experience the same or similar grade  3 or higher unsolicited 
adverse event that is assessed as at least possibly related to the treatment  
• Any Suspected  Unexpected  Serious  Adverse  Reaction  (SUSAR)  (considered  by the Sponsor 
to be possibly or probably related to treatment)  
• Any death  or life-threatening SAE  regardless of relationship to vaccine  
• Any type 1 acute myocardial  infarction  
Dosing may be resumed  following  review  of available  safety  data by the DMC, as  specified  in 
the DMC Charter.  
8.3 Injection  Site Reactions  
Injection -site reactions are expected to spontaneously subside. Local pruritus and pain can be 
treated with oral medications. If significant symptoms of pain and induration persist for more than 12 hours, an ice pack  may be applied  locally  for 30 minutes  every  2 hours, as  needed. Use 
of an ice pack prior to 12  hours after the  onset of symptoms is discouraged, as it may interfere 
with the action  of the  study  vaccine. Do  not inject into a site if local  pain, tenderness, swelling, 
or pruritus persist from a previous injection or other cause.  
8.4 Observation Period  After  Study  Vaccine Injection  
Subjects  will be observed for safety  for a minimum of 30 minutes  after each  study vaccine 
injection. See Section 10.0 for reporting of adverse events.  
8.5 Other  Supportive  Care  
Subjects should receive appropriate supportive care measures as deemed necessary by the investigator. The investigator should ensure that adequate medical care is provided to a subject for any adverse events (AEs)  related  to the study. For each  disorder, attempts  should be made  to 
rule out other causes, which might require additional supportive care. The investigator should  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  49 of 79  
 inform  the study medical  monitor  when  medical  care is needed  for intercurrent illness(es)  of 
which the investigator becomes aware.  
 
An unscheduled visit (UNS)  should be performed  if there  are suspected  subject  safety  concerns. 
All supportive therapies will be recorded in the subject’s electronic case report form (eCRF).  
Subjects  who are discontinued from the study will complete  the Early  Discontinuation/EOS 
Visit, if possible, not earlier than 28 days following their vaccine administration.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  50 of 79  
 9 STUDY PROCEDURES  
9.1 Informed  Consent,  Screening,  and Eligibility  
9.1.1 Informed Consent  
The investigator or designee  must  review  the informed  consent  form (ICF)  with each prospective 
subject to be certain that the prospective subject understands the procedures and risks of the 
study. Prospective subjects who wish to participate in the study must provide written informed 
consent by signing the ICF before undergoing any screening procedures.  
The information  from  the consent  form should be translated  and communicated  to the subject  in 
language understandable to the subject and/or legal representative.  
A copy of the signed and dated  consent  form  should be offered  to the subject  or subject’s legally 
acceptable representative before participation in the study. The subject or his/her legally 
acceptable representative should be informed in a timely manner if new information becomes 
available that may be  relevant to  the subject’s willingness to continue participation in the study. 
The communication of this information should be documented. 
The investigator or designee will maintain  a log of all subjects  who sign the ICF. At  a minimum, 
the log will  include a subject identifier, the  dates of informed consent and screening procedures, 
the outcome of the screening, and, if a  screen failure, the reason the subject did not enroll in the 
study. Other items that will be collected on consented participants are age, sex, ethnicity and 
race. These will be captured in the study database.  
Additional  requirements  for informed  consent  are presented  in Section  13.2.  
9.1.2 Screening  and Eligibility  
After written consent is obtained, screening procedures must be carried out per the Schedule of Events  (Appendix 1). Subjects  who fail screening  may not be rescreened. Subjects may have  the 
screening window extended an additional 7 -calendar days if they have equivocal laboratory 
results or if they cannot be enrolled during the screening window. The screening window may only be extended one time and must have prior approval by the sponsor’s medical monitor.  A 
subject must meet all of the inclusion criteria  and none of the  exclusion criteria  to be eligible to 
participate  in the study (Section  5.0). Documentation to support  a subject’s eligibility  must  be in 
the study records.  
9.1.3 Demographics  and Medical  and Medication  History  
Demographic  and baseline characteristics of sex, race,  ethnicity, age, weight,  and height  of the 
subject will be collected.  
Medical  history  includes  clinically  significant  diseases and surgeries.  Concomitant  medications 
(Section 7.5 ) used by the subject within 28 days prior to Day 1 of the study will be recorded.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  51 of 79  
 9.2 Study  Visits  
Procedures  should be performed  as close  to the scheduled time as possible. A  detailed  outline  of 
all scheduled study procedures is provided in the Schedule of Events ( Appendix 1).  
The exact  time at which  a procedure  is performed  should be recorded in the subject’s  study 
records or appropriate worksheet (if applicable).  
Blood collection  must  be performed  prior  to administration  of the study vaccine on each vaccine 
administration day. 
An Unscheduled  (UNS) Visit (Section  9.5) should be performed  if there  are suspected  subject 
safety concerns. All supportive therapies will be recorded in the subject’s CRF.  
All subjects  should be followed  for at least 28 days after the last study vaccine  injection 
(Section 9.6 ). 
9.3 Immunogenicity  Assessments  
All immunogenicity  assessments will be performed  in a blinded manner  in participating 
laboratories.  
9.3.1 Antibodies  to rF1V  
Serum  samples will be obtained to measure antibodies  against  rF1V. On  vaccine days, samples  
will be collected  prior to administration  of study vaccine.  Standardized 
used to determine serum concentrations of antibodies to rF1V. 
9.4 Safety  Assessments  will be 
The measures of safety in  the study are routine clinical and laboratory  procedures. Safety will be 
assessed  by the reporting  and analysis of post-injection  reactions  (PIRs),  AEs,  SAEs,  AESIs,  and 
deaths ( Section 10.0). The safety assessments are described below. The timing for Safety 
Assessments is provided in the Schedule of Events (Appendix 1). 
9.4.1 Vital Signs  
Vital signs will include oral temperature and measurements of heart rate, respiratory rate, 
systolic  and diastolic  blood pressure. Vital  signs  taken  at the Day 1, Day 29, and Day 183 visits 
will be measured prior to study vaccine administration.  
Vital signs  will be  recorded as indicated  in the Schedule  of Events  (Appendix 1). Bridge  ELISA  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  52 of 79  
 , Day 
 9
 and Day 183 9.4.2 Physical  Examinations  
The investigator or qualified  designee  will conduct  physical  examinations. A complete  physical 
examination is conducted at Screening. A symptom -directed physical exam at all other 
timepoints as outlined in Appendix 1. 
9.4.3 Laboratory Assessments 
Laboratory assessments are listed below and will be performed according to the Schedule of 
Events  (Appendix 1). Sample  collections  will be prior to  administration  of the study vaccine on 
injection days. 
• HIV,  HBV,  HCV  testing  at Screening  Visit 
• Pregnancy testing: For female of childbearing potential (ie, onset of menarche), a serum 
pregnancy test will be performed at screening and must be negative for the subject to participate.  Additionally,  a urine  pregnancy test will be performed  within  24 hours  prior  to 
administration of each study vaccine and must be  negative for the  subject to receive study 
injection.  
• Chemistry Panel: sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), 
creatinine,  glucose, calcium,  aspartate transaminase  (AST),  alanine  transaminase (ALT), 
lactate dehydrogenase (LDH), bilirubin, alkaline phosphatase  
• Hematology:  red blood cell count, hemoglobin, hematocrit,  white  blood cell  count  with 
differential, and platelet count  
• Reserve serum  aliquot  specimens will  be collected  and stored  frozen  at a central  location for 
possible future testing  
Additional  details for collection  and processing of laboratory  samples are provided in the 
Laboratory Manual.  
9.4.4 Post-Injection  Reaction  Assessments 
Assessments  of PIRs  (Section  10.2) will be collected  for a minimum of 30 minutes  following 
each study injection at the clinical site.  
On Day 1 Day 29, and Day 183, subjects  will be asked  to complete  an e-diary  (or equivalent) to 
record any solicited local (pain, redness, pruritus [itchiness], and swelling at the injection site) and solicited systemic signs and symptoms (fatigue, temperature, chills, malaise, myalgia, gastrointestinal symptoms, and headache) during the 7- day follow -up period after vaccination. 
The severity of the post -injection reactions will be graded using the Toxicity Grading Scale for 
Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (Appendix 2 ). 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  53 of 79  
 PIRs persisting beyond 7 days after each study injection are considered AEs and should be 
recorded  and reported  as AEs.  These  will be included in the electronic  data capture (EDC)  AE 
dataset.  
PIRs inadequately recorded by the subject in the e -diary and occurring during the diary period 
from  Day 1 through Day 7 following each study injection  can be reconstructed  by the investigator 
in the AE CRF page. These will be included in the EDC AE dataset.  
Refer  to the eCRF completion  guidelines  for additional  details.  
9.4.5 Adverse Events  
All AEs, as defined in Section 10.0, will be evaluated and reported from immediately after the 
study vaccine injection  on Day 1 through EOS  (Week  56 or Early  Discontinuation) Visit. See  the 
Schedule of Events ( Appendix 1) for the AEs collection schedule.  
9.4.5.1  Serious  Adverse Events  
All SAEs, as defined in Section 10.7.1, whether assessed as related or not related to study 
vaccine injection, will be evaluated from the time the consent is signed through completion of 
the subject’s  participation  in the study  (EOS  Visit). Any  SAE  must be  reported  to Dynavax or its 
designee within 24 hours of knowledge of the event.  
If the  SAE  is assessed  as possibly or probably related  to study  treatment, it  must  be followed 
until it is considered stable or resolved, including beyond the EOS Visit.  
Any SAE assessed  as not related  to study treatment will be followed  as clinically  indicated  until 
its resolution or, if non -resolving, until it is considered chronic or stable, or until study 
completion (EOS Visit).  
9.4.5.1.1 Type  1 Acute  Myocardial  Infarction  (AMI)  
SAEs  of myocardial  infarction  will be further classified  as Type  1 AMI if they  meet  the 
following criteria (Thygesen, Alpert et al. 2018 ): 
• Detection  of a rise and/or  fall of cardiac troponin (cTn) values  with at least 1 value  above  the 
99th percentile upper reference limit and at least 1 of the following: 
• Symptoms  of acute myocardial  ischemia  
• New ischemic ECG changes  
• Development  of pathological  Q waves  
• Imaging  evidence  of new loss of viable  myocardium  or new regional  wall motion 
abnormality in a pattern consistent with an ischemic etiology  
• Identification  of a coronary thrombus  by angiography including intracoronary  imaging  or 
by autopsy  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  54 of 79  
  
9.4.6 Concomitant Medications  
All concomitant  medications  must  be recorded  in the subject’s  CRF  according to Section  7.5 and 
per the Schedule of Events (Appendix 1). 
9.5 Unscheduled Visit  for Safety  
An UNS  Visit should be performed  if there  are suspected  subject  safety  concerns. Procedures  for 
the visit will depend on the reason  for visit as determined  by the treating  principal investigator or 
sub-investigator. If an UNS Visit is performed because of a safety concern related to study 
treatments, at a minimum, the following should be performed:  
• A targeted  physical  examination  based  on subject -reported  symptoms  including measurement 
of vital signs (heart rate, blood pressure, respiratory rate, and temperature). For additional 
details, see Section 9.4.1 and Section 9.4.2. 
9.6 Duration  of Follow -up 
All subjects should be followed  for at least 28 days after administration  of the  study  vaccine.  If a 
subject  is discontinued early  from  the study, an Early  Discontinuation/EOS  assessment  should be 
conducted not earlier than 28 days after the last administration of study vaccine ( Section 9.7).  
9.7 Early  Discontinuation/End of Study  
An EOS Assessment is required at Week 56 (Day 393) in alignment with the protocol, GCP as 
defined in International Council for Harmonisation (ICH) guidelines and US Code of Federal Regulations (CFR), and applicable local regulatory requirements. The EOS procedures will be 
performed  as an Early  Discontinuation assessment at  least 28 days after the last study  injection  if 
the subject is permanently discontinued early from the trial. Investigators are responsible for 
monitoring the safety of subjects throughout the course of the study and for providing appropriate medical care. The investigator will perform all tasks directly or is responsible for overseeing and training qualified site personnel as  delegated to perform study tasks. In addition, 
investigators are responsible for alerting Dynavax to any event that seems unusual and for reporting all AEs, SAEs, pregnancies, and deaths in the appropriate CRFs. 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  55 of 79  
 10 ADVERSE EVENTS  
10.1 Definition  of Adverse Events  
An AE is any untoward medical occurrence associated with the use of a drug, whether or not 
considered  drug related.  An AE can  therefore  be any unfavorable  and unintended sign (including 
a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the study treatment.  
Medical conditions present at Screening (ie, before informed consent is obtained) or present before the study vaccine injection (Day 1) are not AEs and are not recorded on the AE CRF. 
These medical conditions should be adequately documented on the Medical History CRFs. Any 
increase in severity  or frequency of a medical  condition documented as medical  history  after the 
study vaccine injection will be recorded as an AE and will be captured on the AE CRF.  
Post-injection reactions ( Section 10.2 ) persisting beyond 7 days after each study injection are 
considered  to be  AEs and need  to be  recorded  and reported as AEs.  These  will be included in the 
electronic data capture (EDC) AE dataset.  
If a PIR is inadequately recorded by the subject in  the e -diary and occurred during the diary 
period from Day 1 through Day 7 following each study injection, the investigator can retrospectively  evaluate  and report  at their discretion  (as a health  care provider),  as necessary, 
through the date of onset on the AE CRF page. These data will be included in the EDC AE 
dataset.  
An uncomplicated pregnancy is not an AE or SAE  and should not be reported  as an AE/SAE. 
Subjects should be followed as described in Section 10.9. 
The reporting  period for all non-serious AEs begins  at the time of the first study vaccine 
injection (Day 1) through EOS. All AEs will be captured on the AE CRF. The investigator will  follow  all related  non-serious AEs  observed during the study until the AEs 
are considered  resolved  or until EOS.  Dynavax or the Dynavax designee may  request  additional 
follow -up on specific unresolved events.  
AEs should be documented in terms  of a single  medical  diagnosis. When this is not possible, the 
AE should be documented in terms of signs and/or symptoms observed by the investigator or 
reported by the subject.  
Any Grade  3 (severe) solicited  or unsolicited  AE that is considered possibly or probably related 
to treatment must be reported to Dynavax or its designee within 24 hours of investigator 
awareness of the event.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  56 of 79  
 10.2 Definition  of Post -Injection  Reactions  
Post-injection reactions persisting beyond 7 days after injection are considered to be AEs and 
need to be recorded and reported as AEs. The severity of the post -injection reactions will be 
graded using  the Toxicity  Grading Scale for Healthy  Adult  and Adolescent  Volunteers  Enrolled 
in Preventive Vaccine Clinical Trials ( Appendix 2).  
Certain  local  and systemic events  are routinely  monitored in vaccine clinical trials  as indicators 
of vaccine reactogenicity. It is recognized that each of these events, and particularly those of 
systemic nature, may under  certain circumstances, in an individual  subject, have a  cause that is 
unrelated to study vaccine. However, as a matter of convenience and in accordance with common clinical practice, such events occurring within a specified period of time after immunization are herein termed ‘post -injection reactions’ and will be considered as related to 
treatment.  
Post-injection  reactions documented by the subject  will be collected  via a diary, reviewed  by the 
study nurse/coordinator with the subject and recorded appropriately.  
10.3 Overdoses  
If an AE is  associated  with or resulted  from an overdose  of study vaccine (for the purpose  of this 
study defined as more than twice the protocol -specified dose), it will be documented on the AE 
CRF. If it is an SAE, it will also be  reported to Dynavax or the Dynavax designee following the 
SAE reporting process (see Section 10.9.2).  
10.4 Adverse Events  Associated  With  Cancer  
If an AE is  associated with or resulted  from cancer, it  will be  documented on the AE CRF.  If it is 
an SAE, it will also be reported to Dynavax or the  Dynavax designee following the SAE 
reporting process (see Section 10.9.2).  
 
 
10.5 Definition  of Adverse Reaction  
An adverse reaction  (AR)  is defined as any AE caused  by the use of a pharmaceutical  product. 
ARs are a subset of all suspected AEs for which there is reason to conclude that the 
pharmaceutical product caused the event.  
10.6 Definition  of Suspected  Adverse Reaction  
Suspected  adverse  reaction  (SAR)  means any AE for  which  there  is a reasonable  possibility that 
the study treatment caused the AE. Reasonable possibility means there is evidence to suggest a 
causal relationship between the study treatment and AE. An SAR implies a lesser degree of 
certainty about causality than AR, which means an AE caused by a study treatment.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  57 of 79  
 10.7 Definition  of Unexpected  Adverse Event  or Unexpected  Suspected  Adverse 
Reactions  
An AE or SAR is considered  unexpected  if it is not listed  in the Investigator’s  Brochure  or the 
approved product label or is not listed at the specificity or severity that has been previously 
observed.  
10.8 Definition  of Immune -mediated  Adverse Event  of Special  Interest  
Immune -mediated  adverse  events  of special  interest  (imAESI) are defined  according to a pre- 
specified list of event terms including autoimmune, autoinflammatory, and hypersensitivity disorders (Appendix 3). Each subject will be assessed for AESIs  during the entire trial.  
10.9 Serious  Adverse Events  
10.9.1  Definition  of Serious  Adverse Events  
An AE is considered  an SAE  if it meets  any of the following criteria: 
• Results in death  
• Is life-threatening  
Note:  An AE or SAR is considered  life-threatening if, in the view  of either the investigator  or 
sponsor, its occurrence places the subject at immediate risk of death. It does not include an 
AE or SAR that, had it occurred in a more severe form, might have caused death.  
• Requires  in-patient  hospitalization  or prolongs  existing hospitalization  
• Results in persistent  or significant disability  or incapacity  
That is, the event  severely  or permanently  disrupts  the subject's  ability  to perform normal  life 
functions or daily activities.  
• Results in a congenital  anomaly or birth  defect  
• Is medically  significant  (Important  Medical Event)  
Medical and scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate  in other  situations,  such as important  medical  events  that may not be immediately 
life-threatening or result in death  or hospitalization  but may jeopardize the subject. Examples 
of such events are allergic bronchospasm requiring treatment in an emergency room, serious 
blood dyscrasias, or seizures/convulsions that do not result in hospitalization. The 
development  of drug dependence  or drug abuse  would also be examples of important  medical 
events.  
Note: Elective  surgery is not an SAE.  Additionally, an Emergency  Room  visit does not fulfill the 
criteria of hospitalization by definition of an SAE.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  58 of 79  
 10.9.2  Serious  Adverse Event Reporting  Requirements  
Any SAEs, including serious imAESIs, that occur from the time of signed consent through the 
EOS  Visit,  whether or not  the SAE is  related  to the study vaccine  must  be reported  to Dynavax 
or its designee within 24 hours of investigator awareness of the event . The contact 
information  for reporting  SAEs  will be  provided  to each site. General  SAE  reporting  instructions 
are as follows:  
• Submit SAE  documents  according  to instructions  provided.  
• Record  all SAEs  on the AE CRF.  
• For SAEs,  record  the primary  event  on the AE CRF;  describe  events  occurring  secondary  to 
that primary event on the SAE form in the narrative description of the case.  
• Death  is an outcome, not  an event. Record the event  that resulted  in the death  as the fatal 
event on the AE CRF.  
• For hospitalizations for surgical or diagnostic procedures, record the illness leading to the surgical  or diagnostic  procedure  as the SAE,  not the procedure  itself. Capture  the procedure 
in the narrative as part of the action taken in response to the illness.  
• Elective hospitalizations will not be considered SAEs and do not need to be reported. Complications  that prolong  elective hospitalizations  should be recorded  as SAEs.  Emergency 
room visits of less than 24 hours do not meet the criterion of hospitalization for SAE 
reporting purposes.  
 
The SAE  report  should contain,  at a minimum,  the following  information: 
• Subject  identifiers  (ie, subject  number)  
• Suspected  medicinal  product  
• AE term (must  be listed as  serious)  
• Contact  information  for person reporting  event  
The relationship  of the  SAE  to study vaccine will be assessed  by the investigator (Section  10.2). 
Follow -up information should be actively sought and submitted as it becomes available. 
The investigator will assess relationship to study treatment. In addition, the sponsor will assess relationship  to study treatment and determine  expectedness to study vaccine based  on the current 
study vaccine Investigator's Brochure and USPI. The sponsor will report all study vaccine suspected unexpected serious adverse reactions (SUSARs) to regulatory  authorities as expedited 
reports in accordance with applicable regulatory requirements (eg, 21 CFR 312.32[c] and 314.80[e] in the US). All other SAEs will be reported as part of regulatory safety updates, as required, such as in annual reports.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  59 of 79  
 10.10 Adverse Event  Severity  and Relationship  to Study  Treatment  
10.10.1  Severity  Grading  of Adverse Events  and Abnormal  Laboratory Test Results  
The severity  of AEs and laboratory  abnormalities  will be graded  based  on the United  States  Food 
and Drug Administration’s (FDA) Guidance for Industry: Center for Biologics Evaluation and 
Research  (CBER)  Toxicity  Grading Scale for Healthy  Adult  and Adolescent  Volunteers  Enrolled 
in Preventive Vaccine Clinical Trials in Appendix 2, with the modification that, by convention, all fatal AEs will be graded as Grade 5 (Fatal).  
All AEs  not listed in  the CBER  toxicity  grading scale  will be  graded as  shown in Table 10- 1. 
Table 10- 1: Grading Scale for Adverse Events Not Included in the CBER 
Guidance  on Toxicity  Grading  for Healthy  Volunteers in Vaccine 
Clinical Trials  
 
AE Severity  Definition  
Grade  1 – Mild No interference  with activity  
Grade  2 – Moderate  Some  interference  with activity,  not requiring  medical  intervention  
Grade  3 – Severe  Prevents  daily  activity  and requires  medical  intervention  
Grade  4 – Potentially  life-threatening  Emergency  room  visit or hospitalization  
Grade  5 Death  
CBER = Center  for Biologics  Evaluation  and Research.  
 
For all AEs and SAEs,  if there  is a change  in the severity  after the event  onset, the  event  should 
be reported as a single entry with the maximum severity grading captured.  
10.10.2  Relationship of  Adverse Events  to Study  Treatment  
The investigator will determine  the relationship  of the AE to  study vaccine  using the definitions 
provided in Table 10- 2. 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  60 of 79  
 Table 10- 2: Definitions  for Relationship  of Adverse Events to  Study  Treatment  
 
Relationship  to 
Study  Vaccine  
Definition  
Not Related  Another  cause of  the event  is most  plausible;  or clinically plausible  temporal  sequence 
is inconsistent with the onset of the event and the study treatment administration; or a 
causal relationship is considered biologically implausible.  
Possibly  Related  An event  that follows  a reasonable temporal  sequence  from  administration  of the study 
treatment or  a known or expected  response  pattern  to the suspected  drug,  but that could 
readily have been produced by a number of other factors.  
Probably Related  An event that follows  a reasonable temporal sequence from administration  of the study 
treatment, and there is a biologically plausible mechanism for study treatment causing 
or contributing to the AE, and the event could not be reasonably explained by the 
known characteristics  of the subject’s  clinical  state.  In addition,  the relationship  may be 
confirmed by improvement on stopping the study treatment and reappearance of the 
event on repeated exposure.  
AE = adverse  event.  
 
If the  SAE  is assessed  as possibly or probably related  to study  vaccine,  the SAE  must  be 
followed until it is considered resolved, chronic or stable, including beyond EOS.  
Any SAE assessed  as not related  to study vaccine  will be followed  as clinically  indicated  until its 
resolution or, if non- resolving, until it is considered chronic or stable, or until 28 days after the 
last study vaccine injection or until EOS.  
The sponsor  may request  additional  follow -up on specific unresolved AEs.  
10.11  Reporting  and Documentation  of Pregnancy  and Exposure  during 
Breastfeeding  
Any subject  who becomes pregnant  will be followed to pregnancy outcome  even  until after study 
conclusion. Subjects who begin breastfeeding during the study will be followed to EOS or 28 
days after last study injection. Follow -up information should be actively sought by the 
investigator and submitted to Dynavax or designee as soon as it becomes available. The 
investigator will complete the pregnancy reporting form and all other relevant eCRFs.  
Uncomplicated pregnancies are not considered an AE/SAE. A complicated pregnancy or a 
pregnancy with an adverse  outcome  may meet  criteria  for an AE or SAE  and would then also be 
reported according to the appropriate requirements. 
A subject who becomes pregnant will be instructed to report the pregnancy to the study site as 
soon as possible. The subject should be  followed by the investigator  through the pregnancy for 
safety  assessments  and pregnancy outcome  (including beyond EOS).  A report  of the  pregnancy 
will be completed by the investigator or designee and will document details of the pregnancy, outcome of pregnancy, and details of delivery.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  61 of 79  
 Pregnancies and breastfeeding that occur from Day 1 through EOS or 28 days after the last 
administration  of the study  vaccine must  be reported  by the investigator.  The sponsor  or designee 
must be notified as soon as possible once the study site learns of a pregnancy or breastfeeding.  
Pregnancy report  forms  provided by the sponsor or  designee  must  be completed  and reported  to 
Dynavax or its designee within 24 hours of investigator awareness of the event . 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  62 of 79  
 Bridge  ELISA  11 STATISTICAL  METHODS  
Part 1 objectives will be evaluated descriptively. The administration method  of vaccine utilized 
in Part 2 of the study will be selected by Dynavax in consultation with the DoD after Day 57 
immunogenicity  data become  available to determine  whether the  GMC 1 month after 2  doses  of 
rF1V  vaccine with CpG 1018 using the selected  administration  method is at least 2 times  higher 
than that 4 weeks  after 2 doses of rF1V vaccine in Group 3. 
The proposed statistical planning for Part 2 is presented according to the objectives. No 
multiplicity  adjustments  are made,  and all statistical tests will be conducted at 5% two-sided 
Type I level unless otherwise specified.  
All analyses of demographics, medical history, and safety will be summarized in a descriptive manner. In general, continuous variables will be summarized by number of subjects, mean, standard  deviation, median,  quartiles,  minimum and maximum,  and categorical  variables will be 
summarized by number and percentage of subjects in each study group as appropriate. No 
specific safety hypotheses will be tested.  
11.1 Sample Size  Considerations  
Part 2 primary  objective  1 is to assess  the utility of a 2-dose schedule  of rF1V  vaccine with CpG 
1018 as measured by reduction in time to onset of predicted rF1V protection. The predicted 
protection will be based on a Bridge ELISA titer threshold. Previous animal studies have 
established protective efficacy in animals. Since a human efficacy study is not feasible, an  
immunobridge  from animal  data to human data via the test will be used to predict  
the protective efficacy in humans using a regression model. An initial predicted protection 
threshold  will be calculated  based  on the data generated  in this study in Group 3 after 3  doses  of 
rF1V vaccine. Once the threshold is  identified, it will be applied  to the study  groups  in Part 2 of 
the study to evaluate the objectives. In addition to the previous animal studies conducted to establish  protective  efficacy, a new animal model  utilizing  rF1V  vaccine with CpG 1018 will be 
developed to establish the protective level of antibody for CpG 1018 containing vaccines.  
Additional  analyses will include  a predicted  protection threshold that will be calculated  based  on 
the data generated  under  the new animal  model  after 2  doses  of rF1V  vaccine  with CpG  1018. In 
both instances, the animal -to-human immunobridge and the identification of the predicted 
protection thresholds will be documented in a separate report.  
A similar approach  was used to analyze the previous  Phase 2a and Phase 2b study data using the 
animal model from the  previous animal studies. Thresholds that corresponded to 50% predicted 
protective efficacy in humans were established for those trials. In a pooled analysis of these previous immunobridge studies, 93% (95% Clopper Pearson confidence interval [CI] = 85%, 98%) of subjects reached the predicted protection threshold.  
It is assumed that a similar percentage of the subjects in Group 3 will reach the threshold 
identified  in this study. When this threshold is applied  to both Part 2 study  groups, a  similar 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  63 of 79  
 Bridge  ELISA  211 lower bound of the 95% CI is desired across the groups. Table 11-1 shows the lower bound of 
95% Clopper Pearson  CI for different observed levels  of predicted  protection assuming  85 of the 
90 planned subjects (Part 1 N =  20 and Part 2 N =70) will have data available for the evaluation. 
Thus, with a predicted protection level of 93%, the lower bound of the 95% CI would be 85%.  
Table 11-1: Precision  Estimate  at Various Level  of Predicted  Protection  Using 
Clopper Pearson CI (N=85)  
 
Predicted  Protection  Level  Lower Bound  of 95%  CI Upper Bound  of 95% CI 
95% 88% 99% 
93% 85% 97% 
91% 82% 96% 
When the lower bound of 95% CI for the predicted protection after 2 doses of rF1V vaccine 
with CpG 1018 (ie, at Week  8) is similar  to that (after 3  doses of rF1V vaccine (ie, at Week  30), 
the reduction of onset time to predicted rF1V protection is demonstrated.  
11.2 Study  Analysis Populations  
The Safety  Population will comprise  all subjects who receive at least 1 dose of the study 
vaccine, excluding subjects who have no on-study data.  
The Modified intent -to-treat (mITT) populatio n will comprise all eligible subjects who 
received  at least 1 dose of study vaccine and have a post- injection  immunogenicity  evaluation.  
The Per-protocol (PP)  Population for the immunogenicity analyses  will comprise Groups 1 and 
2 subjects who received 2 doses of study vaccine and Group 3 subjects who received 3 doses of study vaccine, have no major protocol deviations (to be specified in the statistical analysis plan), 
and have immunogenicity data obtained within the study visit window at Day 211. 
Further details  of statistical  considerations are provided in a separate  Statistical  Analysis Plan.  
11.3 Demographics and Baseline Characteristics 
Demographic and baseline characteristics will be listed by subject and summarized using the 
Safety Population. Descriptive summary statistics (sample size, mean, median, SD, and range, when  appropriate) will be provided for the continuous variables such as age, weight, and height. 
Count and percentage will be reported  for categorical variables such as sex, race, and ethnicity.  
11.4 Immunogenicity  Endpoints  
The primary  and other immunogenicity endpoints will be analyzed  using the mITT  population. 
Sensitivity analyses on immunogenicity data will also be presented using the PP population.  
Immunogenicity  will be measured  by serum  rF1V  concentration at each visit.  
Part 2 Primary  Objective 1: To assess  the utility  of a 2-dose schedule of rF1V  vaccine with CpG 
1018 as measured by reduction in time to onset of predicted rF1V protection 

Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  64 of 79  
 Bridge  ELISA  
Bridge  ELISA  
Bridge  ELISA  
Bridge  ELISA  
Bridge  
 
Part 2 Exploratory  Objective  1: To assess  long term clinical  benefit  from  rF1V  vaccine  with CpG 
1018 compared with rF1V vaccine  
Endpoint:  Risk ratio of subjects with 2' 6 months clinical benefit between  rFlV  vaccine with 
CpG 1018 and rF1V vaccine  
Criterion for evaluation: 2' 6 months clinical benefit is defined as retaining the predicted 
protection  antibody level  for 2' 6 months. Previous rF1V  vaccine data showed  a small  percentage 
of subjects  who received 3 doses of rF1V  vaccine had 2' 6 months clinical benefit. Similar levels 
are expected for those who received 2 doses of rF1V vaccine with CpG 1018.  Endpoint: predicted  protection (percentage of subjects reaching  the threshold that 
corresponds to 50% predicted vaccine efficacy) at Week 8 after 2 doses of rF1V vaccine with  
CpG 1018 as that at Week  30 after 3 doses of rF1V  vaccine without CpG 1018  
Percentage of subjects reaching the  threshold and associated 95% two -sided 
Clopper- Pearson  confidence intervals  will be computed. Fisher’s  exact  tests will be used  to 
compare predicted protection rate between study groups.  
Criterion  for evaluation: similar percentage of subjects reaching  the threshold that 
corresponds to 50% predicted vaccine efficacy after 2 doses of rF1V vaccine with CpG 1018 as 
compared to that after 3 doses of rF1V vaccine.  
Part 2  Primary  Objective 2: To assess  the serum concentration to rF1V  vaccine 
with CpG 1018 compared with rF1V vaccine 28 days after the second dose of vaccine  
Endpoint: Ratio  of geometric  mean  ELISA  concentration (GMC)  between  rF1V  vaccine with 
CpG 1018 and rF1V vaccine at Week 8 
Criterion  for evaluation: 2- times  increase in GMC point estimate  after the second 
dose of rF1V vaccine with CpG 1018 to that after the second dose of rF1V vaccine.  
 
Criteria  for secondary objectives are GMC and seroconversion rate point estimates from  rF1V 
vaccine with CpG 1018 to meet or exceed results from rF1V vaccine at relevant visits.  
Data  from Part 1  subjects and Part 2 subjects  will be combined to evaluate the Part 2 objectives. 
No multiplicity adjustment is proposed as the Part 1 objectives are not evaluated against the 3- 
dose regime control group. 
11.5 Safety  Analyses  
Safety data will be analyzed descriptively and will be based on the Safety Population. Summary 
statistics will be used to describe the incidence of all post- injection  reactions,  AEs,  AESIs,  SAEs, 
and deaths. Tables of adverse events will include incidence, severity, seriousness, and relationship to the investigational vaccines.  

Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  65 of 79  
 11.6 Interim  Analysis  
This study has no planned interim  analysis.  
12 DATA QUALITY ASSURANCE 
The study sites will be monitored by Dynavax or its designee according to GCP and standard 
operating procedures. Prior to initiation of the study, representatives from Dynavax or its designee will review with the site personnel information about the investigational product, proper  storage  of study treatments,  protocol  requirements,  and monitoring  requirements.  During 
and after the study, periodic on- site and remote visits will be conducted to monitor for 
compliance, including verification of the accuracy and completeness of data recorded on the CRFs, source documents, and study treatments accountability records.  
13 ETHICS  
The protocol and informed consent documents must be reviewed and approved by an appropriately composed Institutional Review Board (IRB). The study will not be initiated at a site until appropriate written IRB approval of the protocol, ICF, and all recruiting materials (if applicable) is  obtained by the investigator. Copies  should be reviewed  and approved by Dynavax 
prior to submission to the IRB. The investigator will submit periodic reports on the progress of the study as required by the IRB, in  accordance  with applicable governmental  regulations, and in 
agreement with the policy established by Dynavax. In addition, the investigator will inform the 
IRB of any protocol amendments  and administrative changes  and will obtain appropriate written 
IRB approval of all protocol amendments.  
13.1 Ethical Conduct  of the Study  
This study will be conducted in accordance with the protocol; GCP as defined in International 
Council  for Harmonisation  (ICH)  guidelines  and US CFR  Title  21, Parts  11, 50, 54, 56, 312, and 
Title 45 Parts 46, 160 and 164; the EU Directives  2001/20/EC and 2005/28/EC; the Declaration 
of Helsinki (1989); IRB Guidelines; and applicable local legal and regulatory requirements.  
13.2 Informed Consent  
The investigator is responsible for maintaining the  privacy and confidentiality of the subject’s 
medical or health  information  collected during the  in compliance with US  CFR Title 21  Part 50, 
Title 45 Part 46 and ICH and IRB guidelines. Prior to initiation of the study at the site, the ICF form must be reviewed and accepted by Dynavax and approved by the governing IRB. The investigator or authorized designee will discuss the purpose and pertinent details of the study with each subject,  and the subject  must  understand, sign, and date the appropriate  IRB- approved 
ICF before undergoing any study- specific procedures. The ICF must be personally signed and 
dated by the subject and by the person who conducted the informed consent discussion. Additional  signature  requirements  may exist.  The original signed and dated  ICF will be retained 
with the subject’s study records, and a copy of the signed ICF will be made available to the  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  66 of 79  
 subject. The  investigator  or designee  will maintain  a log of all subjects  who sign the ICF. 
Screening log content is described in Section 9.1.1. 
13.3 Subject  Confidentiality  
The investigator is responsible for maintaining the  privacy and confidentiality of the subject’s 
medical  or health  information  collected  during the study. The investigator  is also responsible  for 
ensuring that all use, review, and disclosure of subject’s medical or health information is in 
accordance with the Health Insurance Portability and Accountability Act (HIPAA) regulations and with local/regional requirements and that the ICF is approved by the IRB and signed by the subject.  
13.4 Data  Handling  and Record Keeping  
13.4.1  Source  Documents  
The investigator must maintain  detailed  records  of all study subjects  who are enrolled  in the 
study or who undergo screening. Source documents include, but are not limited to, subject medical records and investigator’s subject study files, as well as all test results.  
The following minimum  information  should be entered  into the enrolled subject’s source 
documents:  
• The date the subject  entered  the study  (received  study injection) and the subject  number  
• The study protocol  number  and the name  Dynavax  Technologies  or Dynavax 
• The date that informed  consent/assent  was signed/obtained  
• Evidence  that informed  consent/assent  was obtained before  the subject  underwent  any study-  
specific procedures  
• Evidence  that the subject  meets  study  eligibility  requirements (e.g., medical  history,  study 
procedures, evaluations)  
• The dates  of all study- related  subject  visits  
• Evidence  that study -required  procedures and/or  evaluations  were  completed  
• Use of any concurrent  medications  
• Documentation of study  drug accountability  
• Subject  e-diary  (or equivalent)  entries  
• Occurrence and status of any AEs 
• The date the subject  exited  the study,  and a notation as to whether  the subject  completed  the 
study or was discontinued early, including the reason for discontinuation  
• Any deviations  from the protocol  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  67 of 79  
 13.4.2  Direct Access to Source  Data/Documents  
Qualified individuals designated by Dynavax or its  representative will monitor all aspects of the 
study at regular intervals throughout the study and following study completion. This monitoring 
is for the purpose of verifying adherence to the protocol including appropriate storage of study treatment, completeness and exactness of the data being entered onto the CRFs, and compliance 
with FDA or other regulatory agency regulations. The investigator and investigator’s institution 
agree to allow these monitors access to all study records, CRFs, and corresponding portions of the subject’s clinical study files; to allow access to the clinical supplies, dispensing, and storage areas; and if requested, to assist the monitors. The investigator further agrees to permit direct access  to source data/documents  for study -related  monitoring,  audits, IRB review,  and regulatory 
inspection(s). 
In certain  circumstances,  a secondary  audit  may be conducted by members  of Dynavax’s  Clinical 
Quality Assurance group or by Dynavax’s designated representative. The investigator will be 
notified if this is to take place and advised as to the nature of the audit.  
13.5 Case  Report Forms 
Case report forms  (CRFs) will be  used at the clinical study site to collect  study data for enrolled 
subjects.  For screen  failures,  the sponsor  will collect,  at a minimum,  age, sex, ethnicity,  race,  the 
reason for screen failure and any SAEs that occur during the screening period.  
When  data are available,  authorized clinical  study  site personnel  will carefully  and accurately 
record the data on the CRFs. Sites must ensure that all source documents are maintained 
according to ICH/GCP guidance and support the data that are entered onto the CRFs. 
Case report forms will be in electronic form (eCRFs) for this study. The eCRF data will be 
captured in a system validated according to procedures that comply with 21 CFR Part 11, and 
ICH Guidelines  for GCP  E6 (R2), November  2016, Section 5.5. The eCRFs  will be reviewed  and 
signed by the principal investigator or someone clinically qualified and identified on the delegation log as someone that can sign -off on the eCRF.  
13.6 Data Handling  
The sponsor may designate a Contract Research Organization (CRO) to perform data management. The CRO will write a data management plan outlining the data management systems, procedures, and  agreements between  the CRO  and sponsor. The  plan will be reviewed 
and signed by a representative of the sponsor’s data management department.  
Outside the electronic data capture (EDC) system, when appropriate, the sponsor or designee 
(CRO) will  receive FDA 21 CFR  Part 11 (or locally  required  equivalent) compliant  external  lab 
data transfers  from a validated  laboratory  information management system and subject reported 
safety information from a validated electronic patient report outcome (ePRO) system.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  68 of 79  
 After database  lock, the  investigator will receive a copy of the  subject  data for archiving at the 
study site.  
Validation checks will be conducted to capture data errors, and data clarification queries will be 
generated at the time of data monitoring. Validation checks and queries will be issued to the investigational  site for resolution, and the database will be updated to reflect  query resolutions  as 
appropriate.  
Data verification against the  source documents will be performed by the sponsor or its designee 
prior to locking of the study database. Following the completion of source data verification, a thorough review  of data  will be completed  manually  by the clinical  data managers  to ensure  data 
consistency and to identify and request correction  of any remaining data errors. All queries will 
be resolved or closed with written documentation providing reasons for irresolvable queries.  
Additional  manual validation  checks will be performed as  needed.  
13.7 Coding  of Adverse Events, Drugs, and  Diseases 
AEs and medical  histories  will be coded  using a current  version of the  MedDRA. Prior and 
concomitant medications will be coded according to the World Health Organization Drug Dictionary.  
13.8 Record  Retention  
The investigator must retain  all records  relating  to the conduct  of this study  (including  subject’s 
study records, receipt and disposition of all investigational materials, subject exclusion logs, 
signed consent forms, eCRFs, all correspondence, and other supporting documentation) for at least 2 years after a marketing application for this  indication is approved; or if an application is 
not filed or not approved for the drug for this indication, for at least 2 years after clinical development for the drug has been formally discontinued and the appropriate regulatory or health authorities have been notified. However, in certain instances, documents may need to be 
retained for a longer period if required by regulatory requirements or by an agreement with Dynavax.  
The investigator may  withdraw  from  the responsibility of retaining  records only after transferring 
custody of the records to another individual who will accept responsibility for them. A written 
notice of transfer must be provided to Dynavax prior to or no later than 10 days after transfer.  
The investigator must allow  representatives of the FDA, the  governing IRB, or  other  regulatory 
agencies to inspect all study records. If informed of such an inspection, the investigator will notify Dynavax within 24 hours of being informed. 
The investigator must obtain  written  approval  from Dynavax prior  to the destruction  of any 
records relating to the conduct of this study.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  69 of 79  
 14 USE  OF INFORMATION AND PUBLICATION  
No information related to data obtained and generated in this study shall be released or 
publicized without  the prior  written  consent  of an  Agreements Officer Representative of the U.S. 
Government. 
Any publication will have  the following statement  to acknowledge  the support  of the 
Government whenever publicizing the study in any media:  
This project has been funded in part by the U.S. Government under Agreement W911QY -21-9- 
0018. The  US Government  is authorized to  reproduce  and distribute  reprints for Governmental 
purposes notwithstanding any copyright notation thereon.  
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  70 of 79  
 15 REFERENCES  
Arunachalam, P. S., A. C. Walls, N. Golden, C. Atyeo, S. Fischinger, C. Li, P. Aye, M. J. 
Navarro, L. Lai, V. V. Edara, K. Röltgen, K. Rogers, L. Shirreff, D. E. Ferrell, S. Wrenn, D. Pettie, J. C. Kraft, M. C. Miranda, E. Kepl, C. Sydeman, N. Brunette, M. Murphy, B. Fiala, L. Carter, A. G. White, M. Trisal, C. -L. Hsieh, K. Russell -Lodrigue, C. Monjure, J. Dufour, S. 
Spencer,  L. Doyle -Meyer,  R. P. Bohm,  N. J. Maness,  C. Roy,  J. A. Plante,  K. S. Plante,  A. Zhu, 
M. J. Gorman, S. Shin, X. Shen, J. Fontenot, S. Gupta, D. T. O’Hagan, R. Van Der Most, R. Rappuoli, R. L. Coffman, D. Novack, J. S. McLellan, S. Subramaniam, D. Montefiori, S. D. Boyd, J. L. Flynn, G. Alter,  F. Villinger,  H. Kleanthous, J. Rappaport, M. S. Suthar, N. P. King,  
D. Veesler  and B. Pulendran (2021).  "Adjuvanting a subunit  COVID- 19 vaccine to induce 
protective immunity." Nature . 
Center for Biologics  Evaluation and Research (2007). Guidance  for Industry:  Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, U.S. Department of Health and Human Services, Food and Drug Administration. 
Daya,  M. and Y. Nakamura  (2005). "Pulmonary disease from biological  agents:  anthrax, plague, 
Q fever, and tularemia." Crit Care Clin  21(4): 747- 763, vii.  
Dynavax Technologies  Corporation (2021). HEPLISAV -B SmPC.  
Dynavax Technologies Corporation, P. I. (2020). "HEPLISAV -B® Package Insert." 
Halperin,  S. A., B. Ward,  C. Cooper, G. Predy, F. Diaz -Mitoma,  M. Dionne, J. Embree,  A. 
McGeer,  P. Zickler, K.  H. Moltz, R.  Martz,  I. Meyer, S. McNeil,  J. M. Langley, E. Martins, W. 
L. Heyward  and J. T. Martin  (2012). "Comparison of safety  and immunogenicity  of two doses  of 
investigational hepatitis B virus surface antigen co -administered with an immunostimulatory 
phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in 
healthy adults 18- 55 years of age." Vaccine 30 (15): 2556- 2563. 
Hart, M.  K., G. A.  Saviolakis,  S. L. Welkos  and R. V. House  (2012). "Advanced  Development  of 
the rF1V and rBV A/B Vaccines: Progress and Challenges." Advances in preventive medicine  
2012: 731604- 731604. 
Heyward,  W. L., M. Kyle, J. Blumenau, M. Davis,  K. Reisinger,  M. L. Kabongo, S. Bennett, R.  
S. Janssen,  H. Namini and J. T. Martin  (2013). "Immunogenicity  and safety  of an investigational 
hepatitis B vaccine with a Toll -like receptor 9 agonist adjuvant (HBsAg -1018) compared to a 
licensed hepatitis B vaccine in healthy adults 40 -70 years of age." Vaccine 31(46): 5300- 5305. 
Hinnebusch, B. J. and D. L. Erickson  (2008). "Yersinia  pestis biofilm in the flea vector and its 
role in the transmission of plague." Curr Top Microbiol Immunol  322: 229 -248. 
Hsieh,  S.-M., M.-C. Liu, Y.-H. Chen,  W.-S. Lee, S.-J. Hwang,  S.-H. Cheng, W.-C. Ko, K.-P. 
Hwang,  N.-C. Wang, Y.-L. Lee,  Y.-L. Lin, S.-R. Shih, C.-G. Huang, C.-C. Liao, J.-J. Liang, C. - 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  71 of 79  
 S. Chang, C. Chen,  C. E. Lien,  I.-C. Tai and T.-Y. Lin (2021). "Safety  and Immunogenicity  of 
CpG 1018 and Aluminium Hydroxide -Adjuvanted SARS -CoV- 2 S-2P Protein  Vaccine MVC-  
COV1901: A Large -Scale Double -Blinded, Randomised, Placebo- Controlled Phase 2 Trial." 
medRxiv: 2021.2008.2005.21261532. 
Hsieh,  S.-M., M.-C. Liu, Y.-H. Chen,  W.-S. Lee, S.-J. Hwang,  S.-H. Cheng, W.-C. Ko, K.-P. 
Hwang,  N.-C. Wang, Y.-L. Lee,  Y.-L. Lin, S.-R. Shih, C.-G. Huang, C.-C. Liao, J.-J. Liang, C. - 
S. Chang, C. Chen, C. E. Lien, I. C. Tai and T.- Y. Lin (2021). "Safety and immunogenicity of 
CpG 1018 and aluminium hydroxide -adjuvanted SARS -CoV- 2 S-2P protein vaccine MVC - 
COV1901:  interim results of a large -scale,  double -blind, randomised, placebo- controlled  phase  2 
trial in Taiwan." The Lancet Respiratory Medicine 9(12): 1396- 1406. 
Hsieh,  S.-M., W.-D. Liu, Y.-S. Huang, Y.-J. Lin, E.-F. Hsieh,  W.-C. Lian,  C. Chen, R. Janssen, 
S.-R. Shih, C.- G. Huang, I. C. Tai and S.- C. Chang (2021). "Safety and immunogenicity of a 
Recombinant Stabilized Prefusion SARS -CoV- 2 Spike Protein Vaccine (MVC COV1901) 
Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose - 
escalation study." EClinicalMedicine  38: 100989. 
Hyer, R., D. K. McGuire, B. Xing, S. Jackson and R. Janssen (2018). "Safety of a two- dose 
investigational  hepatitis  B vaccine,  HBsAg -1018, using a toll-like receptor  9 agonist  adjuvant  in 
adults." Vaccine 36(19): 2604- 2611. 
Inglesby, T. V., D. T. Dennis, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. 
Fine, A. M. Friedlander, J. Hauer, J. F. Koerner, M. Layton, J. McDade, M. T. Osterholm, T. 
O'Toole, G. Parker,  T. M. Perl, P. K. Russell,  M. Schoch- Spana  and K. Tonat  (2000). "Plague  as 
a biological weapon: medical and public health management. Working Group on Civilian Biodefense." Jama 283 (17): 2281- 2290. 
Jackson, S., J. Lentino, J. Kopp, L. Murray, W. Ellison, M. Rhee, G. Shockey, L. Akella, K. Erby, W. L. Heyward  and R. S. Janssen  (2018). "Immunogenicity of a two-dose investigational 
hepatitis  B vaccine,  HBsAg -1018, using a toll-like receptor  9 agonist  adjuvant  compared  with a 
licensed hepatitis B vaccine in adults." Vaccine 36 (5): 668 -674. 
Khoury, D. S., D. Cromer, A.  Reynaldi, T. E. Schlub, A. K. Wheatley, J.  A. Juno, K. Subbarao,  
S. J. Kent, J. A. Triccas and M. P. Davenport (2021). "Neutralizing antibody levels are  highly 
predictive  of immune  protection  from  symptomatic  SARS -CoV- 2 infection."  Nature  Medicine  
27(7): 1205 -1211. 
Koirala,  J. (2006). "Plague:  disease,  management, and recognition  of act of terrorism."  Infect Dis  
Clin North Am 20(2): 273 -287, viii.  
McGovern, T. F., A.M. (1997). Plague. Medical Aspects of Chemical and Biological Warfare. 
Washington,  DC, USA,  US Department  of the Army,  Office  of the Surgeon General,  and Borden 
Institute : 479 –502. 
Dynavax  Technologies  Corporation 
rF1V Vaccine with CpG 1018  Protocol  DV2 -PLG -01 
Amendment  5 
CONFIDENTIAL  AND  PROPRIETARY  Page  72 of 79  
 Perry,  R. D. and J. D. Fetherston  (1997).  "Yersinia  pestis --etiologic  agent  of plague."  Clin 
Microbiol Rev  10(1): 35 -66. 
Prentice,  M. B. and L. Rahalison  (2007). "Plague."  Lancet  369(9568):  1196- 1207.  
Richmond, P., L. Hatchuel, M. Dong, B. Ma, B. Hu, I. Smolenov, P. Li, P. Liang, H. H. Han, J. 
Liang and R. Clemens (2021). "Safety and immunogenicity of S -Trimer (SCB -2019), a protein 
subunit  vaccine  candidate  for COVID- 19 in healthy adults:  a phase  1, randomised, double -blind, 
placebo -controlled trial." The Lancet  397: 682- 694. 
Richmond, P. C., L. Hatchuel, F. Pacciarini, B. Hu, I. Smolenov, P. Li, P. Liang, H. H. Han,  J. 
Liang and R. Clemens (2021). "Persistence of the  Immune Responses and Cross -Neutralizing 
Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB -2019 Coronavirus 
Disease 2019 Vaccine." The Journal of Infectious Diseases.  
Vadyvaloo, V., C. Jarrett,  D. Sturdevant, F. Sebbane  and B. J. Hinnebusch  (2007). "Analysis  of 
Yersinia pestis gene expression in the flea vector." Adv Exp Med Biol  603: 192- 200. 
Dynavax  Technologies  Corporation  
rF1V  Vaccine  with CpG  1018  Protocol  DV2 -PLG -01 
Amendment  4 
APPENDIX  1: SCHEDULE  OF TRIAL  EVENTS  
CONFIDENTIAL  AND  PROPRIETARY  Page  73 of 79  
 BRIDGE  ELISA  2
 T
 2
 5
 8
 113 183 211 267 351 
±3) ±3) ±3) ±
 ±7) ±7) ±7) ±7) 
1
 1
 2
 3
 3
 5
 5
 Month  1
 
 
 
Screen - 
inga  
Treat - 
ment   
Follow 
up  
Treat - 
ment   
 
Follow  up  
Treat - 
ment    
Follow  up EOS/  
Early  Discontinuation
b 
(TC)  
393 (±14)  
(Early  discontinuation: 
-28 TC 29 57 85 113 183 211 267 351 28 days  after  
 
 
 
Informed Consent 
Inclusion/Exclusion Criteria 
Demographicse 
Medical  and Medication  Historye 
Vital Signs  f 
Physical  Examg 
HIV, HBV,  HCV  Testingh 
Pregnancy test i 
Serum  chemistryk 
Hematologyl Days 
Weeks 
Months  
X 
X 
X X 
X 
X 
X 
X X 
X 1 4
c 
0 0  
0 
 
 
 
X 
X ( ( ( ( ) (  
4 8 12 16 26 
1 2 3 4 6  
 
  
 
X X 
 
 
X X 
X X  
X X  ( ( (  
30
 38 50 
7 9 12 last study  vaccine) 
56 
13 
Blood  sample for  rF1V  concentrationm 
Blood samples for reserve/exploratory objectivesn X 
Study injections for rF1V vaccine and CpG 1018o 
Study  injections  for rF1V  vaccine and placeboo 
30-minute post -injection observationp 
Distribute  and/or  Review  Subject  e-Diary  or equivalent) 
Instructions  
Review  Subject  e-Diary  (or equivalent)  with Daily 
Temperature and Local/Systemic Reactions j 
Assessment of AEs, SAEs, immune- mediated AESIs q,r Xr 
Concomitant Medications  X X 
X X 
X X 
X X 
X X 
X X 
 
X X 
X X X  
X
 X X  Xd X X  
X X X  
 
  
 
  
 
X
 X X  
X X X  X X X  
X X 
X 
X 
X 
X 
 
X 
X X X X X 
X
 X X X X 
AE = adverse  event;  BP =  blood pressure; CBC  = complete blood  count; HBV  = hepatitis B virus; HCV  = hepatitis  C virus; HIV  = human  immunodeficiency  virus;  HR = 
heart rate; RR = respiratory rate; SAE = serious adverse event; TC= telephone call.  
Dynavax  Technologies  Corporation  
rF1V  Vaccine  with CpG  1018  Protocol  DV2 -PLG -01 
Amendment  4 
CONFIDENTIAL  AND  PROPRIETARY  Page  74 of 79  
 (Bridge  ELISA)  232 days 3
 weeks
 
1, Day 29, and 183 APPENDIX 1: SCHEDULE OF TRIAL EVENTS  (CONT’D)  FOOTNOTES  
Screeninga Routine laboratory tests (serum chemistry, hematology) for screening should be performed within 28 days prior to  enrollment. Subjects may 
have  the screening  window  extended  an additional  7-calendar days if  they have  equivocal  laboratory results  or if they cannot  be enrolled during 
the screening window. The screening window  may only be extended one time and must have prior approval by the sponsor’s medical monitor.  
EOS/Safety  F/Ub A mandatory  EOS/Safety  Follow -up telephone  call will be performed  232 days (30 weeks)  after the administration  of the last study  vaccine.  If 
a subject  receives  received  less than 3 doses  of vaccine,  their EOS visit will  be 28 days  after their last dose.  The EOS  visit procedures  will be 
performed as an Early Discontinuation visit if the subject is permanently discontinued early from the trial.  
Telephone  Callc Telephone  call Day  4 (Part  1 only)  and EOS 
Part 1 Final  immunogenicity 
Assessmentd Part 1 final immunogenicity  assessment  will be conducted  based  on Day 57. 
Demographics/Medical 
History/Prior  Medicationse Demographic  and baseline  characteristics  of sex, race,  ethnicity,  age, weight,  and height,  and medical  history  will be collected.  Report 
complete medication history for 28 days prior to Baseline (Day 1).  
Vital  Signsf Includes  oral temperature  (only  at trial injection  visits),  heart  rate, respiratory  rate, systolic  and diastolic  blood  pressure.  
Physical  Examinationg The investigator  or qualified designee  will conduct  physical  examinations.  A complete  physical  examination  is conducted  at Screening.  A 
symptom -directed physical exam is conducted at all other designated time points.  
HIV,  HBV,  HCV  Testingh HIV,  HBV,  HCV  testing.  
Pregnancy  Testi For females of childbearing potential, a serum pregnancy test will be collected at screening and must be negative for the subject to participate. 
A urine  pregnancy  test must  be negative  within  24 hours  prior to  administration  of each study vaccine.  The test must be negative  for the subject 
to receive study injection.  
Subject  Diaryj At the Day 1 visit,  subjects  are provided  with a ruler,  thermometer  and instructions  for completing  the study  diary. At  Day and 183, 
subjects  are instructed  to complete  the e-diary  (or equivalent)  to record  any solicited  local  (pain,  pruritus,  redness,  and swelling  at the injection 
site) and solicited systemic signs and symptoms (fatigue, chills, myalgia, malaise, fever, gastrointestinal symptoms, and hea dache) during the 
7-day follow -up period after administration of each study vaccine.  
Serum  Chemistryk Chemistry  (includes  sodium,  potassium,  chloride,  bicarbonate,  BUN,  Cr, glucose,  calcium,  AST,  ALT,  LDH,  bilirubin,  alkaline  phosphatase).  
Hematologyl Hematology  includes  red blood  cell count,  Hgb,  hematocrit,  WBC  count  with differential,  and platelet  count.  
Serologym Standardized  enzyme -linked  immunosorbent  assays   to determine  serum  concentrations  of antibodies  to rF1V.  Samples  will be 
drawn  prior  to study  vaccine  injection  on vaccination  days.  The same  sample  will be used for the exploratory  analysis  to determine  serum  
concentrations  of antibodies  to rF1 and rV. 
Reserve  Serum  Aliquotn An extra  aliquot  of serum  collected  and stored  frozen  for possible  future  testing  (drawn  prior  to study  injection  on vaccine  days)  
Study  Vaccine  Administrationo Subjects  will be randomly  assigned  and receive  an injection  of study  vaccine  on vaccination  days.  
If Group  2 is selected  from  the Part  1, then in Part 2, placebo  will not be co-administered  with rF1V.  
Post-Injection  Observationp Subjects will remain  in the clinic  for 30 minutes  after administration  of study  vaccine for observation  of post -injection  local  and systemic 
reactions and AEs.  
Review  AEsq All AEs  will be graded  per CBER  Toxicity  Grading Scale  for Healthy Adult  and Adolescent  Volunteers  Enrolled  in Preventive  Vaccine 
Clinical Trials and evaluated for seriousness. AEs will be collected Day 1 through  Week 56 or Early Discontinuation Visit.  
Review  SAEsr All SAEs will  be evaluated  from  the time the consent  is signed  through  the EOS  Visit.  SAEs  must be  reported  to Dynavax or  its designee 
within 24 hours of the knowledge of the event.  
Dynavax  Technologies  Corporation  
rF1V  Vaccine  with CpG  1018  Protocol  DV2 -PLG -01 
Amendment  4 
CONFIDENTIAL  AND  PROPRIETARY  Page  75 of 79  
 APPENDIX 2:  TOXICITY  GRADING  SCALE FOR  HEALTHY ADULT AND ADOLESCENT VOLUNTEERS  ENROLLED 
IN PREVENTIVE VACCINE CLINICAL TRIALS  
  
Mild  (Grade  1)  
Moderate  (Grade  2)  
Severe (Grade  3) Potentially  Life 
Threatening 
(Grade 4)  
Local  Injection  Site)  Reactions  
Pain Does  not interfere  with 
activity  Repeated use of non -narcotic pain 
reliever  > 24 hours  or interferes  with 
activity  Any use of narcotic  pain reliever  or 
prevents daily activity  Emergency  room  (ER) 
visit or hospitalization  
Tenderness  Mild  discomfort  to touch  Discomfort  with movement  Significant  discomfort  at rest ER visit or 
hospitalization  
Erythema/ Rednessa 2.5 – 5 cm 5.1 – 10 cm > 10 cm Necrosis  or exfoliative 
dermatitis  
Induration/Swellingb 2.5 – 5 cm and does not 
interfere with activity  5.1 – 10 cm or interferes  with activity  > 10 cm or prevents  daily  activity  Necrosis  
Pruritusc No interference  with 
activity  Some  interference  with activity,  not 
requiring medical intervention  Prevents  daily  activity  and requires 
medical intervention  ER visit or 
hospitalization  
Systemic  Reactions  
Fever  (°C) 38.0 – 38.4 38.5-38.9 39.0-40 >40 
Myalgia  No interference  with 
activity  Some  interference  with activity  Significant:  prevents  daily  activity  ER visit or 
hospitalization  
Fatigue  No interference  with 
activity  Some  interference  with activity  Significant:  prevents  daily  activity  ER visit or 
hospitalization  
Malaise  Uneasiness  or lack of well 
being  Uneasiness  or lack of well being;  limiting 
instrumental ADL  A grade  is not available  A grade  is not 
available  
Chillsc No interference  with 
activity  Some  interference  with activity,  not 
requiring medical intervention  Prevents  daily  activity  and requires 
medical intervention  ER visit or 
hospitalization  
Nausea/ 
vomiting  No interference  with 
activity or 1 – 2 
episodes/24 hours  Some  interference  with activity  or > 2 
episodes/24 hours  Prevents  daily  activity,  requires 
outpatient IV hydration  ER visit or 
hospitalization  for 
hypotensive  shock  
Diarrhea  2 – 3 loose  stools  or < 400 
gms 
/24 hours  4 – 5 stools  or 400 – 800 gms/24  hours  6 or more watery stools or > 
800gms/24  hours  or requires  outpatient 
IV hydration  ER visit or 
hospitalization  
Dynavax  Technologies  Corporation  
rF1V  Vaccine  with CpG  1018  Protocol  DV2 -PLG -01 
Amendment  4 
CONFIDENTIAL  AND  PROPRIETARY  Page  76 of 79  
  
  
Mild  (Grade  1)  
Moderate  (Grade  2)  
Severe (Grade  3) Potentially  Life 
Threatening 
(Grade 4)  
Headache  No interference  with 
activity  Repeated  use of nonnarcotic  pain reliever  
> 24 hours  or some  interference  with 
activity  Significant;  any use of narcotic  pain 
reliever or prevents daily activity  ER visit or 
hospitalization  
Systemic  Illness  
Illness  or clinical  adverse  event  (as 
defined according to applicable 
regulations)  No interference  with 
activity  Some  interference  with activity  not 
requiring medical intervention  Prevents  daily  activity  and requires 
medical intervention  ER visit or 
hospitalization  
Source:  (Center  for Biologics  Evaluation  and Research  2007). 
ER = emergency room; IV = intravenous.  
a In addition  to grading  the measured  local  reaction at  the greatest  single  diameter,  the measurement  should be recorded as a continuous  variable.  
b Induration/swelling should  be evaluated  and graded using  the functional  scale as well as the actual  measurement  
c Not part of CBER grading scale.  
Dynavax  Technologies  Corporation  
rF1V  Vaccine  with CpG  1018  Protocol  DV2 -PLG -01 
Amendment  3 
CONFIDENTIAL  AND  PROPRIETARY  Page  77 of 79  
 APPENDIX 3:  LIST OF AUTOIMMUNE CONDITIONS  AND TERMS  OF 
SPECIAL INTEREST  
Any of the conditions listed below that are newly occurring after vaccination are to be 
categorized  as an AESI.  In addition, subjects  with any of the  conditions  listed  below  are 
excluded from the studya. 
Gastrointestinal disorders  
• Celiac disease 
• Crohn’s  disease 
• Ulcerative  colitis  
• Ulcerative  proctitis  
 
Liver  disorders  
• Autoimmune  cholangitis  
• Autoimmune  hepatitis  
• Primary  biliary cirrhosis  
• Primary  sclerosing  cholangitis  
 Metabolic  diseases  
• Addison’s  disease  
• Autoimmune  thyroiditis  (including Hashimoto thyroiditis)  
• Diabetes mellitus  type 1 
• Grave’s or Basedow’s disease  
 Musculoskeletal  disorders  
• Antisynthetase  syndrome  
• Dermatomyositis  
• Juvenile  chronic  arthritis  (including  Still’s  disease)  
• Mixed  connective tissue  disorder  
• Polymyalgia rheumatic  
• Polymyositis  
• Psoriatic  arthropathy  
• Relapsing  polychondritis  
• Rheumatoid  arthritis  
• Scleroderma,  including diffuse  systemic  form  and CREST syndrome  
• Spondyloarthritis, including  ankylosing spondylitis, reactive  arthritis  (Reiter’s  Syndrome) 
and undifferentiated spondyloarthritis  
• Systemic lupus  erythematosus  
• Systemic sclerosis  
Dynavax  Technologies  Corporation  
rF1V  Vaccine  with CpG  1018  Protocol  DV2 -PLG -01 
Amendment  3 
CONFIDENTIAL  AND  PROPRIETARY  Page  78 of 79  
 Neuroinflammatory  disorders  
• Acute  disseminated  encephalomyelitis,  including site specific  variants:  eg, non-infectious 
encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis  
• Cranial  nerve  disorders,  including paralyses/paresis (eg, Bell’s  palsy)  
• Guillain -Barré  syndrome, including Miller Fisher syndrome  and other  variants  
• Tolosa Hunt  syndromeb 
• Immune -mediated  peripheral  neuropathies  and plexopathies  (including chronic 
inflammatory  demyelinating  polyneuropathy, multifocal motor  neuropathy and 
polyneuropathies associated with monoclonal gammopathy)  
• Multiple  sclerosis  
• Myasthenia gravis, including Eaton -Lambert  syndrome  
• Narcolepsy  
• Optic  neuritis  
• Transverse Myelitis  
 
Skin disorders  
• Alopecia  areata 
• Autoimmune  bullous  skin diseases (including pemphigus, pemphigoid  and dermatitis 
herpetiformis) 
• Cutaneous  lupus  erythematosus  
• Erythema nodosum  
• Morphoea  
• Lichen  planus  
• Psoriasis  
• Rosacea  
• Sweet’s syndrome  
• Vitiligo  
 
Vasculitides  
• Large  vessels vasculitis including:  giant  cell arteritis  such as Takayasu’s arteritis  and 
temporal arteritis  
• Medium  sized  and/or  small  vessels  vasculitis including:  polyarteritis  nodosa, Kawasaki’s 
disease, microscopic polyangiitis, Wegener’s granulomatosis, Churg- Strauss syndrome 
(allergic  granulomatous  angiitis),  Buerger’s  disease (thromboangiitis  obliterans),  necrotizing 
vasculitis and anti -neutrophil cytoplasmic antibody (ANCA) positive vasculitis (type 
unspecified), Henoch- Schonlein purpura, Behcet’s syndrome, leukocytoclastic vasculitis  
Dynavax  Technologies  Corporation  
rF1V  Vaccine  with CpG  1018  Protocol  DV2 -PLG -01 
Amendment  3 
CONFIDENTIAL  AND  PROPRIETARY  Page  79 of 79  
 Others  
• Antiphospholipid syndrome  
• Autoimmune hemolytic  anemia 
• Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis  rapidly 
progressive,  membranous  glomerulonephritis, membranoprofilerative  glomerulonephritis, 
and masangioproliferative glomerulonephritis  
• Autoimmune  myocarditis/cardiomyopathy  
• Autoimmune  thrombocytopenia  
• Goodpasture  syndrome  
• Idiopathic  pulmonary fibrosis  
• Pernicious  anemia 
• Raynaud’s  phenomenon  
• Sarcoidosis  
• Sjögren’s syndrome  
• Stevens -johnson syndrome  
• Uveitis  
 
 
a List provided to Dynavax Technologies  by FDA on 30 January  2019  
b Added by Dynavax  